Anti-IL13 antigen-binding protein

Modified anti-IL-13 antibodies with enhanced binding to both human and cynomolgus monkey IL-13 address the affinity gap, providing effective therapeutic options for inflammatory diseases.

JP7949102B2Active Publication Date: 2026-11-11AMGEN INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2025077164
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-26
Filing Date
2025-05-07
Publication Date
2026-11-11
Estimated Expiration
2040-07-24

AI Technical Summary

Technical Problem

Existing anti-IL-13 antibodies exhibit a significant affinity gap between binding to human and cynomolgus monkey IL-13, hindering effective toxicological studies, and there is a need for antibodies with improved affinity for both to treat inflammatory diseases.

Method used

Development of anti-IL-13 antibodies with specific amino acid sequence modifications in the CDRs to enhance binding to cynomolgus monkey IL-13 while maintaining high affinity for human IL-13, utilizing the HuTARG platform to identify variants with improved affinity and potency.

Benefits of technology

The modified antibodies achieve greater than 100-fold improved affinity for cynomolgus monkey IL-13 and 10-fold improved potency in functional biological assays, enabling effective therapeutic applications for inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007949102000055
    Figure 0007949102000055
  • Figure 0007949102000056
    Figure 0007949102000056
  • Figure 0007949102000057
    Figure 0007949102000057
Patent Text Reader

Abstract

To provide an anti-human IL-13 antibody that binds with high affinity not only to human IL-13 but also to cynomolgus monkey IL-13.SOLUTION: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, human monoclonal antibodies directed to IL-13 are provided. Isolated polynucleotide sequences encoding heavy and light chain immunoglobulin molecules, and amino acid sequences comprising the same, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and / or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority and benefit to U.S. Provisional Patent Application No. 62 / 879,335, filed on 26 July 2019, which is incorporated herein by reference in its entirety.

[0002] Sequence listing reference This application includes a computer-readable sequence listing. The sequence listing is provided as a text file named A-2421-WO-PCT_SeqList_ST25.txt, created on 24 July 2020, with a size of 205,493 bytes. The information in the electronic format of this sequence listing is incorporated herein by reference in its entirety.

[0003] This invention relates to the field of biopharmaceuticals. In particular, this invention relates to antibodies and IL-13 binding fragments that specifically bind to human IL-13, and derivatives thereof. This invention also relates to pharmaceutical compositions containing anti-IL-13 for treating inflammatory diseases, and to methods for producing such antibodies. [Background technology]

[0004] IL-13 was the first cytokine recognized for its effects on B cells and monocytes, upregulating class II expression, promoting IgE class switching, and inhibiting the production of inflammatory cytokines. The IL-13 receptor shares the IL-4 receptor alpha chain with the IL-4 receptor. As a result, IL-13 has many biological activities similar to IL-4.

[0005] IL-13 inhibits the release of inflammatory cytokines in vivo and has anti-inflammatory effects. IL-13 plays a role in IgE-mediated allergic reactions and is a central mediator of allergic asthma (Wills-Karp M., Curr. Opin. Pulm. Med., 2003; 9: 21-27). In the lungs, IL-13 regulates eosinophilic inflammation, mucus secretion, and airway hyperresponsiveness. In addition to asthma, IL-13 is involved in the pathogenesis of numerous diseases (Wynn TA. Annu. Rev. Immunol. 2003. 21: 425-456).

[0006] Human antibody Ab731 binds to human IL-13 with high affinity. However, this antibody binds to cynomolgus monkeys (Macaca fascicularis, also referred to as "cyno" IL-13 ("cyIL-13")) with relatively low affinity. Since cynomolgus monkeys are commonly used to evaluate the preclinical safety of antibodies, it is desirable to have an anti-human IL-13 antibody that also binds to cynomolgus monkey IL-13 with high affinity. [Prior Art Documents] [Non-Patent Documents]

[0007] [Non-Patent Document 1] Wills-Karp M., Curr. Opin. Pulm. Med., 2003; 9: 21-27 [Non-Patent Document 2] Wynn TA. Annu. Rev. Immunol. 2003. 21: 425-456 [Summary of the Invention]

[0008] It is desirable that therapeutic antibodies exhibit high affinity binding to both the human ortholog and the cynomolgus monkey ortholog of the therapeutic target. The affinity gap is required to be within a 10-fold affinity window to enable toxicological studies. The AMGN12 antibody, derived from in vivo immunization in XenoMouse®, demonstrated many favorable properties, including single-digit pM affinity for the human ortholog of the target protein. However, this antibody exhibited a 200-fold weaker binding to the ortholog present in cynomolgus monkeys. The purpose of this study was to "close" the affinity gap without compromising binding affinity for the human target, and to lead to the identification of variants with greater than 100-fold improved affinity for the cynomolgus monkey ortholog and 10-fold improved potency in functional biological assays. When the high-resolution crystal structure of the final variant antibody complexed with the target was resolved, it was shown that the affinity-improving mutations obtained by the HuTARG platform are difficult to design a priori in silico.

[0009] The present invention relates to the field of biopharmaceuticals. In particular, the present invention relates to antibodies that specifically bind to human IL-13 and cyno IL-13, IL-13-binding fragments, and derivatives thereof. The present invention also relates to pharmaceutical compositions comprising anti-IL-13 for treating inflammatory diseases, and methods of making such antibodies.

[0010] In embodiments, anti-IL-13 antibodies, antigen (IL-13)-binding fragments, and derivatives (collectively referred to as "antigen-binding proteins") relate to the field of biopharmaceuticals. The present invention relates to anti-IL-13 antibodies and other IL-13 binding proteins that specifically bind to human IL-13. The present invention also relates to pharmaceutical compositions comprising anti-IL-13 antigen binding proteins for treating inflammatory diseases, and methods of making such antibodies.

[0011] In one embodiment of the present invention, minor amino acid sequence changes to the CDRs of Ab731 increase binding to cynomolgus monkey IL-13.

[0012] The present invention includes the following embodiments: 1. An antigen-binding protein that specifically binds to human IL-13, comprising a light chain immunoglobulin variable region (VL1) and a heavy chain immunoglobulin variable region (VH), VL1 comprises (i) CDRL1 containing the amino acid sequence of SEQ ID NO: 11, (ii) CDRL2 containing the amino acid sequence of SEQ ID NO: 12, and (iii) CDRL3 containing the amino acid sequence of SEQ ID NO: 13. VH is an antigen-binding protein containing the amino acid sequences of (i) CDRH1, which contains the amino acid sequence of SEQ ID NO: 8; (ii) CDRH2, which contains the amino acid sequence of SEQ ID NO: 9; and (iii) CDRH3, which contains the amino acid sequence of SEQ ID NO: 10.

[0013] 2. An antigen-binding protein comprising a light chain immunoglobulin variable region (VL1) and a heavy chain immunoglobulin variable region (VH), which specifically binds to human IL-13. VL contains a CDR of the antibody expressed by cell 623, VH is an antigen-binding protein containing the CDR of the antibody expressed by cell 623.

[0014] 3. The antigen-binding protein according to Embodiment 1, further comprising a framework region similar to that of an antibody expressed by cell 623.

[0015] 4. The antigen-binding protein according to any one of Embodiments 1 to 3, wherein the antigen-binding protein is an antibody.

[0016] 5. The antigen-binding protein according to any one of Embodiments 1 to 3, wherein the antigen-binding protein is an antibody fragment.

[0017] 6. The antigen-binding protein according to any one of Embodiments 1 to 3, wherein the antigen-binding protein is a bispecific antibody or an antibody derivative containing a fusion protein.

[0018] 7. The antigen-binding protein according to any one of Embodiments 1 to 6, wherein the antigen-binding protein has a human sequence.

[0019] 8. The antigen-binding protein according to any one of Embodiments 1 to 6, wherein the antigen-binding protein is a monoclonal antibody.

[0020] 9.2 cM to 50 pM K D A human antibody that binds to IL-13.

[0021] K10.2 cM to 40 pM D A human antibody that binds to IL-13.

[0022] 11. A human antibody or antigen-binding fragment thereof that binds to human IL-13, wherein the amino acid sequence is (a) A variable antibody light chain amino acid sequence comprising LCDR1 of SEQ ID NO: 11, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 13; and a variable antibody heavy chain amino acid sequence comprising HCDR1 of SEQ ID NO: 8, HCDR2 of SEQ ID NO: 106, and HCDR3 of SEQ ID NO: 10; (b) A variable antibody light chain amino acid sequence comprising LCDR1 of SEQ ID NO: 11, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 13; and a variable antibody heavy chain amino acid sequence comprising HCDR1 of SEQ ID NO: 8, HCDR2 of SEQ ID NO: 83, and HCDR3 of SEQ ID NO: 10; (c) Variable antibody light chain amino acid sequences including LCDR1 of SEQ ID NO: 11, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 13; and variable antibody heavy chain amino acid sequences including HCDR1 of SEQ ID NO: 8, HCDR2 of SEQ ID NO: 83, and HCDR3 of SEQ ID NO: 10; (d) Variable antibody light chain amino acid sequences including LCDR1 of SEQ ID NO: 74, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 76; and variable antibody heavy chain amino acid sequences including HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10; (e) A variable antibody light chain amino acid sequence comprising LCDR1 of SEQ ID NO: 77, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 76; and a variable antibody heavy chain amino acid sequence comprising HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10; (f) Variable antibody light chain amino acid sequences including LCDR1 of SEQ ID NO: 79, LCDR2 of SEQ ID NO: 12, and LCDR3 of SEQ ID NO: 78; and variable antibody heavy chain amino acid sequences including HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10; (g) Variable antibody light chain amino acid sequences including LCDR1 of SEQ ID NO: 79, LCDR2 of SEQ ID NO: 80, and LCDR3 of SEQ ID NO: 78; and variable antibody heavy chain amino acid sequences including HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10; (h) Variable antibody light chain amino acid sequences including LCDR1 of SEQ ID NO: 81, LCDR2 of SEQ ID NO: 80, and LCDR3 of SEQ ID NO: 78; and Variable antibody heavy chain amino acid sequences including HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10; and (i) A human antibody or antigen-binding fragment thereof, selected from the group comprising: an antibody variable light chain amino acid sequence comprising LCDR1 of SEQ ID NO: 82, LCDR2 of SEQ ID NO: 80, and LCDR3 of SEQ ID NO: 78; and an antibody variable heavy chain amino acid sequence comprising HCDR1 of SEQ ID NO: 107, HCDR2 of SEQ ID NO: 85, and HCDR3 of SEQ ID NO: 10.

[0023] 12. A human antibody or antigen-binding fragment thereof that binds to human IL-13, wherein the amino acid sequence is (a) Antibody variable light chain amino acid sequence containing SEQ ID NO: 86 and antibody variable heavy chain amino acid sequence containing SEQ ID NO: 87; (b) Antibody variable light chain amino acid sequence containing Sequence ID No. 88 and antibody variable heavy chain amino acid sequence containing Sequence ID No. 89; (c) Antibody variable light chain amino acid sequence including SEQ ID NO: 90 and antibody variable heavy chain amino acid sequence including SEQ ID NO: 91; (d) Antibody variable light chain amino acid sequence including SEQ ID NO: 92 and antibody variable heavy chain amino acid sequence including SEQ ID NO: 93; (e) Antibody variable light chain amino acid sequence containing SEQ ID NO: 94 and antibody variable heavy chain amino acid sequence containing SEQ ID NO: 95; (f) Antibody variable light chain amino acid sequence including SEQ ID NO: 96 and antibody variable heavy chain amino acid sequence including SEQ ID NO: 97; (g) Antibody variable light chain amino acid sequence including SEQ ID NO: 98 and antibody variable heavy chain amino acid sequence including SEQ ID NO: 99; (h) Antibody variable light chain amino acid sequence containing SEQ ID NO: 100 and antibody variable heavy chain amino acid sequence containing SEQ ID NO: 101; (i) an antibody variable light chain amino acid sequence containing SEQ ID NO: 102 and an antibody variable heavy chain amino acid sequence containing SEQ ID NO: 103; and (j) A human antibody or its antigen-binding fragment comprising a variable light chain region and a variable heavy chain region selected from the group comprising an antibody variable light chain amino acid sequence containing SEQ ID NO: 104 and an antibody variable heavy chain amino acid sequence containing SEQ ID NO: 105.

[0024] 13. A human antibody or antigen-binding fragment thereof that binds to human IL-13, wherein the amino acid sequence is (a) Light chains selected from the group including SEQ ID NOs: 22, 24, 26, 28, 30, 33, 35, 37; 39, 41; 43, 45, 47, 49, 51, 54, 56, 58, 60, 62, 65, 67, 69, 71, and 73, and (b) A human antibody or antigen-binding fragment thereof comprising a heavy chain selected from the group including SEQ ID NOs: 23, 25, 27, 29, 31, 32, 34, 36; 38, 40, 42, 44, 46, 48, 50, 52, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, and 72.

[0025] 14. An antibody comprising a light chain and a heavy chain having the amino acid sequence described in any one of Embodiments 1-14, 20, or 25-27.

[0026] 15. A nucleic acid sequence encoding an antibody or an antibody fragment according to any one of Embodiments 1 to 14.

[0027] 16. A vector comprising a nucleic acid sequence encoding an antibody or an antibody fragment as described in any one of embodiments 15, 20, 25-27.

[0028] 17. A host cell containing the vector described in Embodiment 16.

[0029] 18. The host cell according to Embodiment 17, wherein the host cell is a CHO cell or a Sp2 / 0 cell.

[0030] 19. The host cell according to Embodiment 18, wherein the host cell is a CHO cell.

[0031] 20. An antibody or antibody fragment produced by a host cell according to any one of embodiments 18 to 19.

[0032] 21. A pharmaceutical composition comprising the antibody or antibody fragment described in Embodiment 20.

[0033] 22. A method for producing an antibody or a fragment thereof by culturing a host cell according to any one of Embodiments 17 to 19.

[0034] 23. A method for treating a patient suffering from COPD, emphysema, asthma, or atopic dermatitis by administering an effective amount of the antibody or fragment thereof described in Embodiment 20 to the patient.

[0035] 24. A method for treating a patient suffering from COPD, emphysema, asthma, or atopic dermatitis by administering an effective amount of the pharmaceutical composition described in Embodiment 21 to the patient.

[0036] 25. The antibody according to Embodiment 20, wherein a half-life extension mutation exists.

[0037] 26. The antibody according to Embodiment 25, wherein the half-life extension mutations are mutations at the Eu positions M252Y, S254T, and T256E within Fc.

[0038] 27. The antibody according to Embodiment 25, wherein the half-life extension mutation is a complement hexamer disruption mutation at the Eu position S583K within Fc. [Brief explanation of the drawing]

[0039] The present invention will be better understood from the embodiments and accompanying drawings, which are intended to be illustrative and not to limit the present invention. [Figure 1] Figure 1 shows a plot of relative antibody concentrations against the neutralization data for each well. The data was used to identify the well with the most potent antibody. [Figure 2] Figure 2 is not a plot showing the relationship between antigen coating, but rather a plot of ELISA OD for each antibody sample with a 31 ng / mL Ag coating against antibody concentration. [Figure 3] Figure 3 is a graph showing the inhibition rates of IL-13-induced eotaxin release by recombinant antibodies 643 and 731 compared to isotype-matched controls. [Figure 4] Figure 4 is a bar graph comparing the ability of IL-13 or IL-13Q110R to inhibit the binding of 731 or 623 to IL-13-coated ELISA plates. [Figure 5A] Figure 5A is a bar graph comparing cell receptor competition between antibody 643 and isotype control. This will probably be changed to 5B. [Figure 5B] Figure 5B is a bar graph comparing cell receptor competition between antibody 731 and isotype control. This will be converted to Figure 5D. [Figure 5C] Figure 5C is a schematic diagram showing the protocol and various prediction results of Figure 5A. [Figure 5D]Figure 5D is a schematic diagram showing the protocol and various prediction results of Figure 5B. This will be changed to 5C. These changes may make tracking easier. [Figure 6A] Figure 6A shows the alignment of a phage display-derived peptide recognized by antibody 693 with a portion of the IL-13 sequence. [Figure 6B] Figure 6B is a chart showing the secondary structure of IL-13, indicating which regions of human IL-13 were replaced with mouse IL-13 to construct the chimeric protein. [Figure 7] Figure 7 is a chart showing various bins that can be used to classify various antibodies. [Figure 8A] Figures 8A and 8B are bar graphs showing that CD4+ T cells derived from humanized IL-13 mice produce human IL-13 but not mouse IL-13. [Figure 8B] Figures 8A and 8B are bar graphs showing that CD4+ T cells derived from humanized IL-13 mice produce human IL-13 but not mouse IL-13. [Figure 9] Figure 9 is a graph showing that anti-IL-13 antibodies 731 and 623 inhibit airway hyperresponsiveness. [Figure 10] Figure 10 is a bar graph showing that 731 and 623 inhibit mucus production. [Figure 11] Figure 11 shows the crystal structure of the interaction between affinity-matured anti-IL-13 antibody and IL-13. [Figure 12A] Figure 12A shows the detailed crystal structure of the interaction between affinity-matured anti-IL-13 antibody and IL-13. [Figure 12B] Figure 12B shows the detailed crystal structure of the interaction between affinity-matured anti-IL-13 antibody and IL-13. [Figure 13] Figure 13 shows the detailed crystal structure of the interaction between affinity-matured anti-IL-13 antibody and IL-13. [Figure 14] Figure 14 is a chart showing the amino acid sequence of a high-affinity anti-IL13 antibody with a half-life extension mutation. [Modes for carrying out the invention]

[0040] Embodiments of the present invention relate to isolated antibodies that bind to IL-13, and methods for using these antibodies to treat diseases in humans. Preferably, the antibodies are fully human neutralizing monoclonal antibodies that bind to IL-13 with high affinity, high potency, or both. In one embodiment, the antibody or antibody fragment specifically binds to a region of the IL-13 molecule, preventing signal transduction of this molecule through the IL-13 receptor complex.

[0041] Furthermore, embodiments of the present invention include methods for using these anti-IL-13 antibodies as diagnostic agents or treatments for diseases. For example, the antibodies may be used for asthma (including both allergic (atopic) and non-allergic (non-atopic)), bronchial asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), hay fever, rhinitis, urticaria, angioedema, allergic dermatitis (including contact dermatitis), Stevens-Johnson syndrome, anaphylactic shock, food allergies, keratitis, conjunctivitis, steroid-resistant glomerulonephritis syndrome, mastocytosis, fibrotic diseases (e.g., pulmonary fibrosis including idiopathic pulmonary fibrosis, cystic fibrosis, bleoma). It is useful in the treatment of isin-induced fibrosis, hepatic fibrosis, and systemic sclerosis, cancer (e.g., Hodgkin's disease), B-cell proliferative disorders (e.g., B-cell lymphoma, especially mediastinal large B-cell lymphoma), B-cell leukemia, ovarian cancer, diseases characterized by non-malignant B-cell proliferation (e.g., systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, and cryoglobulinemia), diseases characterized by high levels of autoantibodies (e.g., hemolytic anemia, thrombocytopenia, phospholipid syndrome, and pemphigus), inflammatory bowel disease, and graft-versus-host disease.

[0042] In connection with such treatments, embodiments of the present invention include products comprising antibodies. One embodiment of the present invention is an assay kit comprising an IL-13 antibody used to screen for diseases or disorders related to IL-13 activity.

[0043] The nucleic acids, as well as their fragments and variants, described herein may, in non-limiting examples, be used (a) as recombinant or heterologous gene products to direct the biosynthesis of corresponding encoded proteins, polypeptides, fragments, and variants; (b) as probes for the detection and quantification of the nucleic acids disclosed herein; and (c) as sequence templates for the preparation of antisense molecules. Such uses are described in more detail below.

[0044] In one embodiment, a method for identifying these antibodies is provided. In one embodiment, the method includes an eotaxin release assay.

[0045] In one embodiment, antibodies that bind to IL-13 variants are also provided. Of particular interest are antibodies that bind to IL-13 variants having glutamine at position 110 of the endogenous IL-13 polypeptide.

[0046] In one embodiment, a mouse humanized for human IL-13 is provided. This mouse is useful for providing a test subject for airway hyperresponsiveness and mucus production inhibition.

[0047] Definition: Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have meanings generally understood by those skilled in the art. Furthermore, unless the context requires a different interpretation, singular terms shall include plural forms, and plural terms shall include singular forms.

[0048] Generally, the nomenclature and techniques used in relation to cell and tissue culture, molecular biology, and protein and oligonucleotide or polynucleotide chemistry, as well as hybridization, as described herein, are well known and commonly used in the art, as described in various general and more specific references cited and discussed throughout this specification. For example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd See also Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)) (incorporated herein by reference). Standard techniques (e.g., electroporation, lipofection) are used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation. Enzymatic reactions and purification techniques are carried out according to the manufacturer's instructions, or as commonly achieved in the art, or as described herein. Standard techniques can also be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and patient treatment.

[0049] When used in accordance with this disclosure, the following terms shall be understood to have the following meanings unless otherwise specified.

[0050] "Polymerase chain reaction," or "PCR," refers to a procedure or method for amplifying specific fragments of nucleic acids, RNA, and / or DNA in minute quantities, as described in U.S. Patent No. 4,683,195, issued July 28, 1987. Generally, sequence information from the end or beyond of the region of interest must be available so that oligonucleotide primers can be designed, and these primers are identical or similar in sequence to the opposite strand of the template being amplified. The 5' terminal nucleotides of two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from whole-genomic DNA, and cDNA transcribed from whole-cellular RNA, bacteriophages, or plasmid sequences, etc. For general information, see Mullis et al., Cold Spring Harbor Symp. Quant. Biol. 51:263 (1987); Erlich, ed., PCR Technology (Stockton Press, NY, 1989). As used herein, PCR is considered an example, but not the only, of nucleic acid polymerase reaction methods for amplifying nucleic acid test samples, which involves the use of known nucleic acids and nucleic acid polymerases as primers for amplifying or generating specific fragments of nucleic acid.

[0051] Antibodies (Ab) and immunoglobulins (Ig) are glycoproteins with the same structural characteristics. Antibodies exhibit binding specificity to specific antigens, while immunoglobulins include both antibodies and other antibody-like molecules that lack antigen specificity. The latter type of polypeptide is produced at low levels by the lymphatic system, for example, and at high levels by myeloma.

[0052] Antibodies are heterotetrameric glycoproteins with approximately 150,000 daltons, consisting of two identical and substantially full-length light (L) chains and two identical and substantially full-length heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, although the number of disulfide bonds differs between heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (VH) at one end, followed by several constant domains. Each light chain has a variable domain (VL) at one end and a constant domain at the other end, with the constant domain of the light chain aligned with the first constant domain of the heavy chain, and the variable domain of the light chain aligned with the variable domain of the heavy chain. It is thought that certain amino acid residues form an interface between the light chain variable domain and the heavy chain variable domain (Chothia et al. J.Mol.Biol.186:651(1985); Novotny and Haber, Proc.Natl.Acad.Sci.USA82:4592(1985); Chothia et al., Nature 342:877-883(1989)).

[0053] "Antibody fragments" include fragments of antibodies that bind to a target antigen. Examples of antibody fragments include Fab fragments, Fab' fragments, F(ab')2 fragments, and Fv fragments.

[0054] As used herein, “antigen-binding protein” means a protein derived from an antibody that specifically binds to a particular antigen. Examples of antigen-binding proteins include, but are not limited to, antibodies, antibody fragments, antibody constructs, fusion proteins, bispecific antibodies, and scFv proteins.

[0055] The antigen-binding protein has a dissociation constant (KD) of ≤ 10, as measured by surface plasma resonance techniques (e.g., BIACore, GE-Healthcare Uppsala, Sweden) or binding equilibrium exclusion methods (KinExA, Sapidyne, Boise, Idaho). -7When M binds to an antigen, we say that the antigen-binding protein "specifically binds" to that antigen.

[0056] The antigen-binding protein of the present invention can neutralize and inhibit the binding of IL-13 to signaling receptors such as IL-13 receptor alpha-1 (IL-13Rα1) by at least 60% or 80%, more commonly, more than about 85% (as measured by an in vitro competitive binding assay). In one embodiment, the antibody also inhibits binding to the decoy receptor IL-13Rα2, while in other embodiments, the ability of IL-13 to bind to IL-13Rα2 is maintained when the antibody binds to IL-13.

[0057] Intact antibodies can be assigned to different "classes" depending on the amino acid sequence of the heavy chain constant domain. There are five main classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy chain constant domains corresponding to various classes of antibodies are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional arrangements of various classes of immunoglobulins are well known.

[0058] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies constituting the population are identical except for any naturally occurring mutations that may be present. Monoclonal antibodies are highly specific and target a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which contain different antibodies targeting different determinants (epitopes), each monoclonal antibody targets a single determinant on the antigen. In addition to their specificity, monoclonal antibodies have the advantage of being able to be synthesized without contamination by other antibodies. The modifier “monoclonal” indicates the characteristic of the antibody to be obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention may be produced by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or by the recombinant DNA method (see, for example, U.S. Patent No. 4,816,567). Monoclonal antibodies may also be isolated from phage antibody libraries using methods such as those described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0059] "Isolated" antibodies are those identified, separated, and / or recovered from components of their natural environment. Contaminations from the natural environment are substances that may interfere with the diagnostic or therapeutic use of the antibody and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the antibody is purified until it exceeds 95% by weight by (1) determination by Lowry method and determination by terminal or internal amino acid sequence using a spinning cup sequencer, or (2) homogenization by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue, or preferably silver staining. Since isolated antibodies lack at least one component of their natural environment, they may contain antibodies present in situ within recombinant cells. However, isolated antibodies are typically prepared by at least one purification step.

[0060] A "neutralizing antibody" is an antibody molecule that can eliminate or significantly reduce the effector function of the target antigen to which it binds. Therefore, a "neutralizing" IL-13 antibody can eliminate or significantly reduce effector functions such as IL-13 signaling activity mediated by the IL-13 receptor. In one embodiment, the neutralizing antibody reduces the effector function by 1-10%, 10-20%, 20-30%, 30-50%, 50-70%, 70-80%, 80-90%, 90-95%, 95-99%, and 99-100%.

[0061] "Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated response in which nonspecific cytotoxic cells expressing Ig Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize antibodies bound to target cells, subsequently causing lysis of the target cells. NK cells, the primary cells mediating ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). To evaluate the ADCC activity of a target molecule, an in vitro ADCC assay (e.g., those described in U.S. Patent No. 5,500,362 or 5,821,337) can be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, the ADCC activity of the target molecule can be evaluated in vivo in animal models, such as those disclosed in Clynes et al. PNAS (USA) 95:652-656 (1988).

[0062] The term "variable" refers to the fact that certain parts of the variable domain differ significantly in sequence between antibodies, and this is used in the binding and specificity of each particular antibody to its particular antigen. However, variability is not evenly distributed throughout the variable domain of an antibody. In both the Ig light chain and heavy chain variable domains, variability is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions. The more highly conserved parts of the variable domain are called framework regions (FRs). The variable domains of the natural heavy and light chains each contain four FR regions, mostly in a β-sheet configuration, which are connected by three CDRs that form loop connections and sometimes form part of the β-sheet structure. The CDRs of each chain are held together in close proximity by the FR regions and, together with the CDRs of other chains, contribute to the formation of the antibody's antigen-binding site (see Kabat et al. (1991)). The constant domain does not directly participate in the antibody's binding to the antigen, but exhibits various effector functions, such as the antibody's involvement in antibody-dependent cytotoxicity.

[0063] Digestion of antibodies by the enzyme papain yields two identical antigen-binding fragments, also known as "Fab" fragments, and an "Fc" fragment that lacks antigen-binding activity but possesses crystallization ability. Digestion of antibodies by the enzyme pepsin yields an F(ab')2 fragment, in which the two arms of the antibody molecule remain linked and contain two antigen-binding sites. The F(ab')2 fragment has antigen-crosslinking ability.

[0064] As used herein, "Fv" refers to the smallest fragment of an antibody that retains both an antigen recognition site and an antigen binding site.

[0065] As used herein, "Fab" refers to an antibody fragment containing the constant domain of the light chain and the CH1 domain of the heavy chain.

[0066] "Fv" is the smallest antibody fragment containing a complete antigen recognition site and antigen binding site. In double-stranded Fv species, this region consists of a dimer of one heavy chain variable domain and one light chain variable domain that are tightly non-covalently bonded. In single-stranded Fv species, the one heavy chain variable domain and one light chain variable domain may be covalently bonded by a flexible peptide linker so that the light and heavy chains can associate in a "dimeric" structure similar to that in double-stranded Fv species. In this configuration, the three CDRs of each variable domain interact to define the antigen binding site on the surface of the VH-VL dimer. In total, six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific CDRs) has the ability to recognize and bind to an antigen, albeit with lower affinity than the entire binding site.

[0067] A "fusion protein" refers to a protein that contains an antibody fragment bound to another protein.

[0068] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody responsible for antigen binding. The hypervariable region generally consists of amino acid residues derived from the "complementarity-determining region" or "CDR" (e.g., residues 24-34 (L1), 50-62 (L2), and 89-97 (L3) of the light chain variable domain, and residues 31-55 (H1), 50-65 (H2), and 95-102 (H3) of the heavy chain variable domain); Kabat et al., Sequences of Proteins of Immunological Interest, 5 thThis includes residues from the "hypervariable loop" (e.g., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) of the light chain variable domain, and residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) of the heavy chain variable domain; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). The "framework region" or "FR" residues are variable domain residues other than the hypervariable region residues as defined herein.

[0069] The terms “complementarity-determining region” or “CDR,” as used herein, refer to the portion of an immune receptor that comes into contact with a particular ligand and determines its specificity. The CDR of an immune receptor is the most variable portion of the receptor protein, giving the receptor diversity, and is held on six loops located at the distal end of the receptor’s variable domain, with three loops originating from each of the receptor’s two variable domains.

[0070] The term "epitope" is used to refer to the binding site of an antibody on a protein antigen. Epitope determinants are usually surface groups of chemically active molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural properties and specific charge properties. An antibody is said to bind to an antigen when the dissociation constant is ≤1 μM, preferably ≤100 nM, most preferably ≤10 nM. An increased or greater equilibrium constant ("K") is used. D A K of "0" means that the affinity between the epitope and the antibody is lower. In other words, the antibody and epitope are not so favorably bound together or remaining bound together. A decreased or lower equilibrium constant means that the affinity between the epitope and the antibody is higher. In other words, the antibody and epitope are more likely to bind together or remain bound together. A K of "0" to some extent D The presence of this characteristic means that the antibody binds to the epitope with a given affinity, or more strongly (or more closely).

[0071] K D describes the binding properties of epitopes and antibodies, while "potency" describes the inherent effectiveness of the antibody with respect to its function. A relatively low K D does not necessarily mean high potency. Accordingly, an antibody may have a relatively low K D and high potency (e.g., they bind well and potently alter function), a relatively high K D and high potency (e.g., they do not bind well but potently affect function), a relatively low K D and low potency (e.g., they bind well but not in an effective manner to alter a particular function), or a relatively high K D and low potency (e.g., they simply do not bind sufficiently to the target). In one embodiment, high potency means that there is a high level of inhibition at low concentrations of antibody. In one embodiment, an antibody is potent or has high potency if its IC 50 is a small value, for example, 130 to 110, 110 to 90, 90 to 60, 60 to 30, 30 to 25, 25 to 20, 20 to 15, or less pM.

[0072] "Substantially", unless otherwise specified in connection with another term, means that the value may vary within any amount that can contribute to measurement errors that may occur during the creation or practice of the embodiments. "Significant" means that the value may vary so long as it is sufficient to enable the claimed invention to function for its intended use.

[0073] The term "amino acid" or "amino acid residue" as used herein refers to a naturally occurring L-amino acid, or a D-amino acid as further described below with respect to variants. Commonly used one-letter and three-letter abbreviations for amino acids are used herein (Bruce Alberts et al., Molecular Biology of the Cell, Garland Publishing, Inc., New York (3d ed. 1994)).

[0074] The term "mAb" refers to a monoclonal antibody.

[0075] The term "human antibody" refers to an antibody in which the majority (at least 95%) of the antibody sequence is derived from the human genome.

[0076] The term "XENOMOUSE®" refers to mouse strains engineered to contain germline fragments of 245kb and 190kb sizes from the human heavy chain locus and the kappa light chain locus, as described in Green et al. Nature Genetics 7:13-21 (1994) (incorporated herein by reference). XENOMOUSE® strains are available from Abgenix, Inc. (Fremont, CA).

[0077] When used in conjunction with XENOMOUSE® animals, the term "XENOMAX®" refers to the use of the "Selected Lymphocyte Antibody Method" (Babcook et al., Proc. Natl. Acad. Sci. USA, 93:7843-7848 (1996)).

[0078] The term “SLAM®” refers to “Selective Lymphocyte Antibody Method” (Babcook et al., Proc. Natl. Acad. Sci. USA, 93:7843-7848 (1996), and Schrader’s U.S. Patent No. 5,627,052, both of which are incorporated herein by reference in their entirety).

[0079] The terms “disease,” “disease state,” and “disorder” refer to a physiological state of a cell or whole mammal in which there is an interruption, cessation, or impairment of the function, system, or organ of a cell or body.

[0080] The term “symptom” means any physical or observable sign of a disorder, whether or not it is generally characteristic of that disorder. The term “symptom” can mean all such signs or any part thereof.

[0081] The terms “to treat” or “treatment” refer to both therapeutic treatments and preventive or deterrent measures, the purpose of which is to prevent or slow (attenuate) undesirable physiological changes or impairments, such as the onset or spread of cancer. For the purposes of the present invention, beneficial or desirable clinical outcomes include, but are not limited to, symptom relief, reduction of disease severity, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” also means extending survival compared to the survival expected without treatment. Persons requiring treatment include those who already have a condition or impairment, those who are prone to developing a condition or impairment, or those who should be prevented from developing a condition or impairment. When used in conjunction with a disease or symptom, the term “suppress” may mean that an antibody can reduce or eliminate a disease or symptom.

[0082] The term "patient" includes both human and animal subjects.

[0083] For the purpose of treatment, "to administer" means to deliver to the patient. For example, such delivery may be intravenous, intraperitoneal, by inhalation, intramuscular, subcutaneous, oral, topical, percutaneous, or surgical.

[0084] The “therapeutic dose” for the purpose of a treatment means the amount of administration that can result in an observable change in the patient’s condition and / or symptoms, either alone or in combination with other treatments.

[0085] A "pharmaceutically acceptable vehicle" for the purpose of treatment is a physical object that can be administered to a patient. A pharmaceutically acceptable vehicle may be, but is not limited to, pills, capsules, caplets, tablets, oral fluids, injectable fluids, sprays, aerosols, lozenges, nutritional supplements, creams, lotions, oils, solutions, pastes, powders, inhalants, or liquids. An example of a pharmaceutically acceptable vehicle is a buffered isotonic solution such as phosphate-buffered saline (PBS).

[0086] For the purpose of treatment, "neutralizing" means partially or completely inhibiting chemical and / or biological activity.

[0087] "Downregulation" for the purpose of treatment means reducing the level of a specific target composition.

[0088] For the purposes of this procedure, “mammals” means any animal classified as a mammal, including humans, domesticated animals and livestock, as well as zoo animals, sports animals, or pets, such as monkeys, dogs, horses, cats, and cows.

[0089] Where used herein, the term "polynucleotide" means a polymer of nucleotides of at least 10 nucleotides in length, either ribonucleotides or deoxynucleotides, or modified forms of either type of nucleotide. This term includes single-stranded and double-stranded forms of DNA.

[0090] As used herein, the term “isolated polynucleotide” means a genomic polynucleotide, a cDNA polynucleotide, or a polynucleotide of synthetic origin, or any combination thereof, and depending on its origin, an “isolated polynucleotide” is either (1) not associated with all or part of a naturally occurring polynucleotide, (2) operably ligated to a naturally unligated polynucleotide, or (3) not naturally occurring as part of a relatively large sequence.

[0091] As used herein, the term “oligonucleotide” includes naturally occurring nucleotides and modified nucleotides linked together by naturally occurring oligonucleotide bonds and non-naturally occurring oligonucleotide bonds. Oligonucleotides are generally segments of polynucleotides having a length of 200 nucleotides or less. Preferably, oligonucleotides are 10 to 60 nucleotides long, most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides long. Oligonucleotides are usually single-stranded, for example for probes, but oligonucleotides may be double-stranded, for example for use in the construction of gene mutants. Oligonucleotides may be either sense oligonucleotides or antisense oligonucleotides.

[0092] As used herein, the term “naturally occurring nucleotide” includes deoxyribonucleotides and ribonucleotides. The term “modified nucleotide” as used herein includes nucleotides having modified or substituted sugar groups, etc. The term “oligonucleotide linkage” as used herein includes oligonucleotide links such as phosphorothioates, phosphorodithioates, phosphoroselenoates, phosphorodiselenoates, phosphoranilothioates, phosphoraniladates, and phosphoramidates. For example, see LaPlanche et al. Nucl. Acids Res. 14:9081 (1986); Stec et al. J. Am. Chem. Soc. 106:6077 (1984); Stein et al. Nucl. Acids Res. 16:3209 (1988); Zon et al. Anti-Cancer Drug Design 6:539 (1991); Zon et al. Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991)); Stec et al. U.S. Patent No. 5,151,510; Uhlmann and Peyman Chemical Reviews 90:543 (1990) (these disclosures are incorporated herein by reference). Oligonucleotides may optionally include labels for detection.

[0093] As used herein, the term “selectively hybridizing” means detectable and specific binding. Polynucleotides, oligonucleotides, and their fragments selectively hybridize to nucleic acid chains under hybridization and washing conditions that minimize a perceptible amount of detectable binding to nonspecific nucleic acids. Selective hybridization conditions known in the art and discussed herein can be achieved using high stringency conditions. Generally, the nucleic acid sequence homology between the polynucleotide, oligonucleotide, or antibody fragment and the nucleic acid sequence of interest is at least 80%, and more typically, it is preferable to increase the homology to at least 85%, 90%, 95%, 99%, and 100%.

[0094] As used herein, the term “regulatory sequence” refers to a polynucleotide sequence necessary to enable the expression and processing of the coding sequence to which they are ligated. The nature of such regulatory sequences varies depending on the host organism; in prokaryotes, such regulatory sequences generally include promoters, ribosome binding sites, and transcription termination sequences, while in eukaryotes, such regulatory sequences generally include promoters and transcription termination sequences. The term “regulatory sequence” is intended to include at least all components whose presence is essential for expression and processing, and may also include additional components whose presence is advantageous, such as leader sequences and fusion partner sequences.

[0095] As used herein, the term “operably linked” refers to the position of a component that is described as being in a relationship that enables the component to function in its intended manner. For example, a control sequence “operably linked” to a code sequence is linked such that the expression of the code sequence is achieved under conditions that conform to the control sequence.

[0096] As used herein, the term “isolated protein” means a protein of cDNA, a protein of recombinant RNA, or a protein of synthetic origin, or any combination thereof, and depending on its origin or source of origin, an “isolated protein” is either (1) not associated with a naturally occurring protein, (2) not containing other proteins of the same origin (e.g., not containing mouse protein), (3) expressed by cells of a different species, or (4) not present in nature.

[0097] The term "polypeptide" is used herein as a general term to refer to native proteins, fragments, or analogs of polypeptide sequences. Thus, native proteins, fragments, and analogs are species of the genus Polypeptide. The polypeptides according to the present invention include, for example, human heavy chain immunoglobulin molecules represented by SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, and 83-105 in Table 21, as well as human kappa light chain immunoglobulin molecules represented by, for example, SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 106-126, and antibody molecules formed by combinations (and vice versa) of heavy chain immunoglobulin molecules and light chain immunoglobulin molecules such as kappa light chain immunoglobulin molecules, as well as fragments and analogs thereof.

[0098] Unless otherwise specified, the left end of a single-stranded polynucleotide sequence is called the 5' end, and the left direction of a double-stranded polynucleotide sequence is called the 5' direction. The direction in which a nascent RNA transcript is added from 5' to 3' is called the transcription direction. A sequence region on a DNA strand with the same sequence as the RNA, located 5' to the 5' end of the RNA transcript, is called the "upstream sequence." A sequence region on a DNA strand with the same sequence as the RNA, located 3' to the 3' end of the RNA transcript, is called the "downstream sequence."

[0099] Where used herein, the 20 conventional amino acids and their abbreviations follow conventional usage. See, incorporated herein by reference, *Immunology--A Synthesis* (2nd Edition, ESGolub and DRGren, Eds., Sinauer Associates, Sunderland, Mass. (1991)). Stereoisomers of the 20 conventional amino acids (e.g., D-amino acids), unnatural amino acids such as alpha,alpha-disubstituted amino acids and N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components of the polypeptides of the present invention. Examples of unconventional amino acids include 4-hydroxyproline, γ-carboxyglutamic acid, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, following standard usage and convention, the left-hand direction is the amino-terminus direction and the right-hand direction is the carboxy-terminus direction.

[0100] The term "corresponding to" is used herein to mean that a polynucleotide sequence is homologous (i.e., identical but not strictly evolutionarily related) to all or part of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence.

[0101] In contrast, the term “complementary to” is used herein to mean that a complementary sequence is homologous to all or part of a reference polynucleotide sequence. For illustrative purposes, the nucleotide sequence “TATAC” corresponds to the reference sequence “TATAC” and is complementary to the reference sequence “GTATA”.

[0102] The following terms—"reference sequence," "comparison window," "sequence identity," "percentage of sequence identity," "substantial identity," and "homology"—are used to describe the sequence relationship between two or more polynucleotide or amino acid sequences. A "reference sequence" is a given sequence used as the basis for sequence comparison. A reference sequence may be a portion of a larger sequence, for example, a segment of a full-length cDNA or gene sequence listed in a sequence listing, or it may contain a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids long, often at least 24 nucleotides or 8 amino acids long, and frequently at least 48 nucleotides or 16 amino acids long. Since each of two polynucleotide or amino acid sequences may (1) contain similar sequences between the two molecules (i.e., a portion of a complete polynucleotide or amino acid sequence) and (2) further contain sequences that differ between the two polynucleotide or amino acid sequences, sequence comparison between two (or more) molecules is usually performed by comparing the sequences of the two molecules across a "comparison window" to identify and compare local regions of sequence similarity.

[0103] As used herein, “comparison window” refers to a conceptual segment of at least about 18 consecutive nucleotide positions or about 6 amino acids, where the polynucleotide sequence or amino acid sequence is compared to a reference sequence of at least 18 consecutive nucleotide positions or 6 amino acid sequences, and the portion of the polynucleotide sequence in the comparison window may contain no more than 20 percent of additions, deletions, substitutions, etc. (i.e., gaps) compared to the reference sequence (which is free of additions or deletions) for optimal alignment of the two sequences. The optimal alignment of sequences for aligning the comparison window can be performed using the local homology algorithm of Smith and Waterman Adv.Appl.Math.2:482 (1981), the homology alignment algorithm of Needleman and Wunsch J.Mol.Biol.48:443 (1970), the similarity search method of Pearson and Lipman Proc.Natl.Acad.Sci.(USA)85:2444 (1988), computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA, GENEWORKS®, or MACVECTOR® software packages in Wisconsin Genetics Software Package, Release 7.0 (Genetics Computer Group, 575 Science Dr., Madison, Wis.)), or by inspection, and the best alignment generated by various methods (i.e., the one that yields the highest percentage of homology across the comparison window) is selected.

[0104] The term "sequence identity" means that two polynucleotide sequences or amino acid sequences are identical across a comparison window (i.e., identical nucleotide-wise or residue-wise). The term "percentage of sequence identity" can be calculated by comparing two optimally aligned sequences across a comparison window, determining the number of positions where nucleic acid bases (e.g., A, T, C, G, U, or I) or amino acid residues are identical in both sequences, finding the number of matching positions, dividing that number of matching positions by the total number of positions within the comparison window (i.e., the window size), and multiplying the result by 100 to obtain the percentage of sequence identity. As used herein, the term “substantial identity” means that the polynucleotide or amino acid sequence contains a sequence that, when compared to a reference sequence over a comparison window of at least 18 nucleotides (6 amino acids) (often a comparison window of at least 24 to 48 nucleotides (8 to 16 amino acids)), has at least 85 percent sequence identity, preferably at least 90 to 95 percent, and more preferably at least 99 percent sequence identity, where the percentage of sequence identity is calculated by comparing the reference sequence over the comparison window with a sequence that may contain deletions or additions totaling no more than 20 percent of the reference sequence. The reference sequence may be a portion of a larger sequence.

[0105] Two amino acid sequences or polynucleotide sequences are “homologous” if there is partial or complete identity between them. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned to maximize the match. Gaps (in either of the two sequences being aligned) are acceptable when maximizing the match, with a gap length of 5 or less preferred, and more preferably 2 or less. Alternatively, and preferably, two protein sequences (or polypeptide sequences derived therefrom, at least about 30 amino acids in length) are homologous as the term is used herein if they have an alignment score greater than 5 (in units of standard deviation) using the ALIGN program with a mutation data matrix and a gap penalty of 6 or more. See Dayhoff, MO, in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 of this volume, pp. 1-10. Two sequences or portions thereof are more preferably homologous if, when optimally aligned using the ALIGN program, their amino acids are identical by 50% or more.

[0106] When applied to polypeptides, the term “substantial identity” means that two peptide sequences, when optimally aligned by a program such as GAP or BESTFIT using default gap weighting, share at least 80 percent sequence identity, preferably at least 90 percent, more preferably at least 95 percent, and most preferably at least 99 percent sequence identity. Preferably, non-identical residue positions are distinguished by conserved amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues with similar side chains. For example, the amino acid group with aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; the amino acid group with aliphatic-hydroxyl side chains is serine and threonine; the amino acid group with amide-containing side chains is asparagine and glutamine; the amino acid group with aromatic side chains is phenylalanine, tyrosine, and tryptophan; the amino acid group with basic side chains is lysine, arginine, and histidine; and the amino acid group with sulfur-containing side chains is cysteine ​​and methionine. The preferred group of conserved amino acid substitutions are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine.

[0107] As discussed herein, slight variations in the amino acid sequence of an antibody or immunoglobulin molecule are intended to be included in the present invention, provided that the variation in the amino acid sequence is maintained by at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%. In particular, conservative amino acid substitutions are intended. Conservative substitutions are substitutions that occur within a family of amino acids and relate to their side chains. Genetically encoded amino acids are generally divided into the families of (1) acidic = aspartic acid, glutamic acid; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) non-charged = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. More preferred families include serine and threonine, which belong to the aliphatic hydroxy family; asparagine and glutamine, which belong to the amide-containing family; alanine, valine, leucine, and isoleucine, which belong to the aliphatic family; and phenylalanine, tryptophan, and tyrosine, which belong to the aromatic family.

[0108] For example, it is reasonable to expect that sole substitution of leucine with isoleucine or valine, sole substitution of aspartic acid with glutamic acid, sole substitution of threonine with serine, or similar substitutions of structurally related amino acids to a given amino acid will not significantly affect the binding or properties of the resulting molecule, especially if the substitution does not involve amino acids within the framework site. Whether an amino acid change results in a functional peptide can be easily determined by assaying the specific activity of the polypeptide derivative. The assay is described in detail herein.

[0109] Fragments or analogues of antibody or immunoglobulin molecules can be readily prepared by those skilled in the art. The preferred amino or carboxyl termini of the fragment or analogue are located near the boundaries of the functional domain. Structural and functional domains can be identified by comparing nucleotide and / or amino acid sequence data with public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains present in other proteins of known structure and / or function. Methods for identifying protein sequences that fold into known three-dimensional structures are known (Bowie et al. Science 253:164 (1991)). The above examples demonstrate that those skilled in the art can recognize sequence motifs and structural conformations that can be used to define structural and functional domains according to the present invention.

[0110] Preferred amino acid substitutions are those that (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for protein complex formation, (4) alter binding affinity, and (5) confer or modify other physicochemical or functional properties of such analogues. Analogues may include various mutant proteins of sequences other than naturally occurring peptide sequences. For example, one or more amino acid substitutions (preferably conservative amino acid substitutions) may be made in naturally occurring sequences (preferably in the polypeptide portion outside the domain that forms intermolecular contacts). Conservative amino acid substitutions should not substantially alter the structural properties of the parent sequence (for example, the substituted amino acids should not tend to disrupt helices present in the parent sequence or other types of secondary structures that characterize the parent sequence). Examples of secondary and tertiary structures of polypeptides recognized in the art are described in Proteins, Structures and Molecular Principles (Creighton, Ed., WH Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, NY (1991)); and Thornton et al. Nature 354:105 (1991), which are incorporated herein by reference, respectively.

[0111] As used herein, the term “polypeptide fragment” refers to a polypeptide having an amino-terminus and / or carboxy-terminus deletion, but whose remaining amino acid sequence is identical to the corresponding position in a naturally occurring sequence, for example, derived from a full-length cDNA sequence. The fragment is typically at least 5, 6, 8, or 10 amino acids long, preferably at least 14 amino acids long, and more preferably at least 20 amino acids long. In other embodiments, the polypeptide fragment is at least 25 amino acids long, more preferably at least 50 amino acids long, and even more preferably at least 70 amino acids long.

[0112] Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs that possess properties similar to those of a template peptide. These types of non-peptide compounds are called "peptide mimes" or "peptidomimetic compounds." (Fauchere, J.Adv. Drug Res. 15:29 (1986); Veber and Freidinger TINS ​​p.392 (1985); and Evans et al. J.Med.Chem. 30:1229 (1987) (these are incorporated herein by reference)). Such compounds are often developed with the assistance of computerized molecular modeling. Peptide mimes that are structurally similar to therapeutically useful peptides can be used to obtain equivalent therapeutic or preventive effects. Generally, peptidomimetic peptides are structurally similar to paradigm polypeptides (i.e., polypeptides with biochemical properties or pharmacological activity), such as human antibodies, but have one or more peptide bonds that are selectively substituted by bonds selected from the group consisting of -CH2NH-, -CH2S-, -CH2-CH2-, -CH=CH- (cis and trans), -COCH2-, -CH(OH)CH2-, and -CH2SO-, by methods well known in the art. To produce more stable peptides, one or more amino acids in the consensus sequence can be systematically substituted with the same type of D-amino acid (e.g., D-lysine instead of L-lysine). Furthermore, restrictive peptides containing the consensus sequence or substantially identical consensus sequence mutations can be produced by methods well known in the art (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992) incorporated herein by reference), for example, by adding internal cysteine ​​residues that can form intramolecular disulfide bridges that cyclize the peptide.

[0113] As used herein, the terms “labeled” or “labeled” refer to the incorporation of a detectable marker, for example, by the incorporation of a radiolabeled amino acid or by the attachment of a biotinyl moiety to a polypeptide that can be detected by a marker-tagged avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity detectable by optical or colorimetric methods). In certain circumstances, the label or marker may also be therapeutic. Various methods for labeling polypeptides and glycoproteins are known and can be used in the art. Examples of labeling polypeptides include, but are not limited to, radioisotopes or radionuclides (e.g., 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I) Fluorescent labeling (e.g., FITC, rhodamine, lanthanide phosphors), enzyme labeling (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescence, biotinyl groups, and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, secondary antibody binding sites, metal-binding domains, epitope tags). In some embodiments, the labeling is attached by spacer arms of varying lengths to reduce potential steric hindrance.

[0114] As used herein, the term “pharmaceutical or drug” means a chemical compound or composition that, when administered appropriately to a patient, can induce a desired therapeutic effect. Other chemical terms herein are used in accordance with the customary usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, S., Ed., McGraw-Hill, San Francisco (1985)), which is incorporated herein by reference.

[0115] As used herein, “substantially pure” means that the species of interest is the dominant species present (i.e., that species is more abundant in molar terms than any other individual species in the composition), and preferably, a substantially purified fraction is a composition in which the species of interest constitutes at least about 50 percent (on a molar basis) of all the polymer species present. Generally, a substantially pure composition constitutes more than about 80%, more preferably more than 85%, 90%, 95%, and 99% of all the polymer species present in the composition. Most preferably, the species of interest is purified to the point of substantial homogeneity (it is impossible to detect any impurities in the composition by conventional detection methods), and the composition essentially consists of a single polymer species.

[0116] Antibody structure The basic antibody structural unit is known to include a tetramer. Each tetramer consists of two identical pairs of polypeptide chains, each pair having one "light" chain (approximately 25 kDa) and one "heavy" chain (approximately 50-70 kDa). The amino-terminus of each chain contains a variable region of approximately 100-110 or more amino acids, primarily responsible for antigen recognition. The carboxyl-terminus of each chain defines a constant region, primarily responsible for effector function. Human light chains are classified into kappa and lambda light chains. Heavy chains are classified into mu, delta, gamma, alpha, or epsilon, defining the antibody isotypes as IgM, IgD, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are linked by a "J" region of approximately 12 or more amino acids, and the heavy chain also contains a "D" region of approximately 10 or more amino acids. (For general reference, see Fundamental Immunology Ch.7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)) (the whole is incorporated by reference for all purposes)). The variable region of each light / heavy chain pair forms the antigen-binding site.

[0117] Therefore, intact antibodies have two binding sites. Except for bifunctional or bispecific antibodies, the two binding sites are identical.

[0118] All chains exhibit the same general structure of a relatively conserved framework region (FR) linked by three hypervariable regions, also called complementarity-determining regions or CDRs. The CDRs derived from the two chains of each pair are aligned by the framework region, thereby enabling binding to specific epitopes. From the N-terminus to the C-terminus, both the light and heavy chains contain domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The amino acid assignments for each domain follow the definitions in Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).

[0119] Bispecific or bifunctional antibodies are artificial hybrid antibodies possessing two different heavy / light chain pairs and two different binding sites. Bispecific antibodies can be produced by various methods, including hybridoma fusion or Fab' fragment linkage (see, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990), Kostelny et al. J. Immunol. 148:1547-1553 (1992)). The production of bispecific antibodies can be a relatively labor-intensive process compared to the production of conventional antibodies, and the yield and purity of bispecific antibodies are generally lower. Bispecific antibodies do not exist in the form of fragments with a single binding site (e.g., Fab, Fab', and Fv).

[0120] Human antibodies and humanization of antibodies Human antibodies avoid some of the problems associated with antibodies that have variable and / or constant regions of mouse or rat. The presence of such mouse or rat-derived proteins can lead to rapid clearance of the antibody or trigger an immune response to the antibody by the patient. To avoid the use of mouse or rat-derived antibodies, fully human antibodies can be produced by introducing human antibody function into rodents so that the rodents produce fully human antibodies.

[0121] One method for producing fully human antibodies involves using the XENOMOUSE® mouse strain, engineered to contain germline fragments of 245kb and 190kb sizes from the human heavy chain locus and the kappa light chain locus. See Green et al. Nature Genetics 7:13-21 (1994). The XENOMOUSE® strain is available from Abgenix, Inc. (Fremont, CA).

[0122] The XENOMOUSE® trademark was created through U.S. Patent Application No. 07 / 466,008 filed on January 12, 1990, No. 07 / 610,515 filed on November 8, 1990, No. 07 / 919,297 filed on July 24, 1992, No. 07 / 922,649 filed on July 30, 1992, No. 08 / 031,801 filed on March 15, 1993, and August 27, 1993. Specification No. 08 / 112,848 filed on [date], Specification No. 08 / 234,145 filed on April 28, 1994, Specification No. 08 / 376,279 filed on January 20, 1995, Specification No. 08 / 430,938 filed on April 27, 1995, Specification No. 08 / 464,584 filed on June 5, 1995, Specification No. 08 / 464,582 filed on June 5, 1995, Specification No. 08 Specification No. / 463,191, Specification No. 08 / 462,837 filed on June 5, 1995, Specification No. 08 / 486,853 filed on June 5, 1995, Specification No. 08 / 486,857 filed on June 5, 1995, Specification No. 08 / 486,859 filed on June 5, 1995, Specification No. 08 / 462,513 filed on June 5, 1995, Specification No. 08 / 724,752 filed on October 2, 1996 Further discussion and description are found in the following documents, and in Patent No. 08 / 759,620 filed December 3, 1996, as well as in U.S. Patents Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598, and in Japanese Patent Publications Nos. 3068180, 3068506, and 3068507. See also Mendez et al. Nature Genetics 15:146-156 (1997) and Green and Jakobovits J. Exp. Med. 188:483-495 (1998).See also European Patent No. 0463151B1, published on June 12, 1996; International Publication No. 94 / 02602, published on February 3, 1994; International Publication No. 96 / 34096, published on October 31, 1996; International Publication No. 98 / 24893, published on June 11, 1998; and International Publication No. 00 / 76310, published on December 21, 2000. The disclosures of each of the patents, applications, and references cited above are incorporated herein by reference in their entirety.

[0123] Another approach, employed by other companies including GenPharm International, Inc., utilizes the "mini-locus" approach. In this mini-locus approach, exogenous Ig loci are mimicked by including small fragments (individual genes) derived from this Ig locus. Therefore, one or more V H gene, one or more D H gene, one or more J HThe gene, the muon constant region, and the second constant region (preferably the gamma constant region) form a construct that is inserted into the animal. This approach is based on U.S. Patent No. 5,545,807 by Surani et al., and U.S. Patents No. 5,545,806, 5,625,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,877,397, 5,874,299, and 6,255,458 by Lonberg and Kay, U.S. Patents No. 5,591,669 and 6,023,010 by Krimpenfort and Berns, and Berns et al. U.S. Patent Nos. 5,612,205, 5,721,367, and 5,789,215 by al., U.S. Patent No. 5,643,763 by Choi and Dunn, and U.S. Patent Application No. 07 / 574,748 filed August 29, 1990, No. 07 / 575,962 filed August 31, 1990, No. 07 / 810,279 filed December 17, 1991, No. 07 / 853,408 filed March 18, 1992, No. 07 / 904,068 filed June 23, 1992, No. 07 / 990,860 filed December 16, 1992, and 1993 These are described in specification No. 08 / 053,131 filed on April 26, specification No. 08 / 096,762 filed on July 22, 1993, specification No. 08 / 155,301 filed on November 18, 1993, specification No. 08 / 161,739 filed on December 3, 1993, specification No. 08 / 165,699 filed on December 10, 1993, and specification No. 08 / 209,741 filed on March 9, 1994 (these disclosures are incorporated herein by reference).See also European Patent No. 0546073B1, International Publication Brochures 92 / 03918, 92 / 22645, 92 / 22647, 92 / 22670, 93 / 12227, 94 / 00569, 94 / 25585, 96 / 14436, 97 / 13852, and 98 / 24884, as well as U.S. Patent No. 5,981,175 (these disclosures are incorporated herein by reference in their entirety). See also Taylor et al., 1992, Chen et al., 1993, Tuaillon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuaillon et al., (1995), Fishwild et al., (1996) (these disclosures are incorporated herein by reference in their entirety).

[0124] Kirin also demonstrated the production of human antibodies from mice into which large chromosome fragments or entire chromosomes were introduced via microcell fusion. See European Patent Applications No. 773288 and No. 843961 (these disclosures are incorporated herein by reference in their entirety).

[0125] Human anti-mouse antibody (HAMA) responses have also led the industry to prepare chimeric or otherwise humanized antibodies. While chimeric antibodies possess both a human constant region and a mouse variable region, specific human anti-chimeric antibody (HACA) responses are expected to be observed, particularly with long-term or multiple-dose use of the antibody. Therefore, it is desirable to provide fully human antibodies against multimeric enzymes to reduce concerns and / or impacts of HAMA or HACA responses.

[0126] Antibody preparation The antibodies described herein were prepared using the XENOMOUSE® technology as described below. Such mice are capable of producing human immunoglobulin molecules and antibodies, and are deficient in the production of mouse immunoglobulin molecules and antibodies. The technology used to achieve the same is disclosed in the patents, applications, and references referenced herein. However, preferred embodiments of transgenic production of mice and antibodies derived therefrom are disclosed in U.S. Patent Application No. 08 / 759,620, filed December 3, 1996, and in International Publication No. 98 / 24893, published June 11, 1998, and International Publication No. 00 / 76310, published December 21, 2000 (these disclosures are incorporated herein by reference). See also Mendez et al. Nature Genetics 15:146-156 (1997) (this disclosure is incorporated herein by reference).

[0127] Using such techniques, fully human monoclonal antibodies against IL-13 were generated, as detailed below. Essentially, XENOMOUSE® mouse strains were immunized with human IL-13, lymphocytes (such as B cells) were collected from the antibody-expressing mice, and these collected cell lines were fused with myeloid cell lines to prepare immortal hybridoma cell lines. These hybridoma cell lines were screened and selected to identify hybridoma cell lines that produce IL-13-specific antibodies. Furthermore, characterization of antibodies produced by such cell lines, including nucleotide and amino acid sequence analysis of the heavy and light chains of these antibodies, is provided herein.

[0128] Alternatively, instead of fusing myeloma cells to create hybridomas, recovered cells isolated from the XENOMOUSE® strain of immunized mice can be further screened for their responsiveness to an initial antigen, preferably human IL-13. Such screenings include ELISA using the desired IL-13 protein and functional assays such as the production of IL-13-induced eotaxin-1. Next, single B cells secreting antibodies that specifically bind to IL-13 can be isolated using the desired IL-13-specific hemolytic plaque assay (Babcook et al., Proc. Natl. Acad. Sci. USA, i93:7843-7848 (1996)). The target cells for lysis are preferably IL-13-coated sheep erythrocytes (SRBCs). In the presence of a B cell culture secreting the immunoglobulin and complement of interest, plaque formation indicates specific IL-13-mediated lysis of the target cells.

[0129] A single antigen-specific plasma cell can be isolated from the center of the plaque, and the genetic information encoding the antibody specificity can be isolated from that single plasma cell. Using reverse transcriptase PCR, the DNA encoding the variable region of the secreted antibody can be cloned. Such cloned DNA can then be further inserted into a suitable expression vector, preferably a vector cassette such as pcDNA (Invitrogen, Carlsbad, CA), more preferably such a pcDNA vector containing constant domains of immunoglobulin heavy and light chains. The resulting vector can then be transfected into host cells, preferably CHO cells, and cultured in a conventional nutrient medium modified to be suitable for promoter induction, transformant selection, or amplification of the gene encoding the desired sequence.

[0130] This specification describes the isolation of multiple single plasma cells that produce antibodies specific to IL-13. Furthermore, genetic material encoding antibodies that specifically bind to IL-13 was isolated, introduced into a suitable expression vector, and then transfected into host cells.

[0131] Generally, the antibodies produced by the aforementioned cell lines contained either fully human IgG single or double chains with human kappa light chains. When measured by either solid or liquid phase, the antibodies were typically around 10 -9 ~about 10 -13 It possessed high affinity with M's KD.

[0132] As mentioned above, anti-IL-13 antibodies can be expressed in cell lines other than hybridoma cell lines. Sequences encoding specific antibodies can be used to transform suitable mammalian host cells, such as CHO cells. Transformation may be by any known method for introducing polynucleotides into host cells, including, for example, packaging polynucleotides in a virus (or viral vector) and transducing the host cell with the virus (or vector), or by transfection procedures known in the art, as exemplified by U.S. Patents No. 4,399,216, No. 4,912,040, No. 4,740,461, and No. 4,959,455 (these patents are incorporated herein by reference). The transfection procedure used depends on the host being transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art, and such methods include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, polynucleotide encapsulation in liposomes, and direct microinjection of DNA into the nucleus.

[0133] Mammalian cell lines available as expression hosts are well known in the art and include, but are not limited to, numerous immortalized cell lines available from the American Type Culture Collection (ATCC), such as Chinese hamster ovary (CHO) cells, Sp2 / 0 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney (COS) cells, human hepatocellular carcinoma cells (e.g., Hep G2), and many other cell lines. Particularly preferred cell lines are selected by determining which cell lines have high expression levels and produce antibodies with IL-13 binding properties.

[0134] antibody sequence The nucleotide and amino acid sequences of the heavy and light chain variable regions of representative human anti-IL-13 antibodies are shown in the sequence listing, and their contents are summarized in Table 1 below.

[0135] [Table 1]

[0136] Antibody therapy drugs Anti-IL-13 antibodies have therapeutic value for treating symptoms and conditions associated with IL-13 activity. IL-13 is involved in a wide variety of diseases and disorders, including inflammatory diseases, cancer, fibrotic diseases, and diseases characterized by non-malignant cell proliferation. In certain embodiments, the anti-IL-13 antibodies disclosed herein are used to treat inflammatory diseases or disorders, such as asthma (including both allergic (atopic) and non-allergic (non-atopic)), bronchial asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), hay fever, rhinitis, urticaria, angioedema, allergic dermatitis (including contact dermatitis), Stevens-Johnson syndrome, anaphylactic shock, food allergies, keratitis, conjunctivitis, and steroid-resistant glomerulonephritis syndrome. In other embodiments, anti-IL-13 antibodies are used to treat mastocytosis. In further embodiments, anti-IL-13 antibodies are used to treat fibrotic diseases such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, cystic fibrosis, bleomycin-induced fibrosis, hepatic fibrosis, and systemic sclerosis. In even further embodiments, anti-IL-13 antibodies are used to treat cancers, such as Hodgkin's disease, B-cell proliferative disorders (e.g., B-cell lymphoma, particularly mediastinal large B-cell lymphoma), B-cell leukemia, and ovarian cancer.

[0137] In yet another embodiment, anti-IL-13 antibodies are used to treat diseases characterized by non-malignant B cell proliferation, such as systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, and cryoglobulinemia; diseases characterized by high levels of autoantibodies, such as hemolytic anemia, thrombocytopenia, phospholipid syndrome, and pemphigus; inflammatory bowel disease; and graft-versus-host disease.

[0138] If desired, the isotype of an anti-IL-13 antibody can be switched, for example, to utilize the biological properties of different isotypes. For example, in some situations, it may be desirable for a therapeutic antibody against IL-13 to be able to immobilize complement and participate in complement-dependent cell-mediated cytotoxicity (CDC). Numerous antibody isotypes exist that can do the same, including, but are not limited to, mouse IgM, mouse IgG2a, mouse IgG2b, mouse IgG3, human IgM, human IgG1, and human IgG3. It is understood that the antibody to be produced does not initially need to have such an isotype; rather, the antibody to be produced can have any isotype, and that antibody can then be isotype-switched using conventional methods well known in the art. Such methods include, among others, the use of direct recombination methods (see, for example, U.S. Patent No. 4,816,397) and cell-cell fusion methods (see, for example, U.S. Patents No. 5,916,771 and 6,207,418).

[0139] As an example, the anti-IL-13 antibodies discussed herein are human antibodies. If the antibody has the desired binding to IL-13, it can be readily isotype-switched to produce human IgM, human IgG1, or human IgG3 isotypes, while still retaining the same variable region (which defines part of the antibody's specificity and affinity). Such molecules can then immobilize complement and participate in CDC.

[0140] In the cell-cell fusion method, a myeloma cell line or other cell line having a heavy chain of any desired isotype is prepared, and another myeloma cell line or other cell line having a light chain is prepared. Such cells are then fused, and a cell line expressing intact antibodies can be isolated.

[0141] Therefore, once antibody candidates that satisfy the desired "structural" characteristics as described above are produced, they can generally be conferred with at least some of the desired "functional" characteristics through isotype switching.

[0142] Biologically active antibodies that bind to IL-13 are preferably used in sterile pharmaceutical preparations or formulations to reduce IL-13 activity. Anti-IL-13 antibodies preferably have an affinity suitable for potent suppression of IL-13 activity within a targeted therapeutic range. The suppression is preferably due to the antibody's ability to interfere with the binding of IL-13 to signaling receptors such as IL-13Ra1 (also known as IL-13Rα1, Rα1, IL-13R-alpha 1, IL-13 receptor alpha 1, or other similar terms). In other embodiments, antibodies can suppress IL-13 activity even if IL-13 is able to bind by interfering with the ability of IL-13 to signal through receptors. For example, an antibody may prevent interaction between IL-13Ra1 and co-receptors necessary for signaling, such as the IL-4 receptor alpha chain. In some embodiments, an antibody can prevent IL-13 activity via signaling receptors while simultaneously allowing IL-13 to bind to decoy receptors such as IL-13Ra2. In this case, binding to the decoy receptor may allow for the clearance of bound IL-13, thereby enhancing the antibody's ability to suppress IL-13 activity.

[0143] When used for in vivo administration, antibody preparations are preferably sterile. This can be easily achieved by any method known in the art, for example, filtration through a sterile filtration membrane. Antibodies are usually stored in lyophilized form or in solution. Sterile filtration may be performed before or after lyophilization and reconstitution.

[0144] Therapeutic antibody compositions are generally filled into containers with sterile access ports, such as intravenous solution bags or vials with adapters that allow for the recovery of the formulation (e.g., stoppers that can be punctured by a subcutaneous needle).

[0145] The mode of administration of antibodies may be by known methods, such as injection or infusion via subcutaneous, intravenous, intraperitoneal, intracerebral, intradermal, intramuscular, intraocular, intraarterial, intrathecal, or intrafocal routes, or by inhalation, or by sustained-release systems as described below. In some situations, antibodies are preferably administered by infusion or bolus injection. In other situations, the therapeutic composition containing the antibody may be administered via the nose or lungs, preferably as a liquid or powdered aerosol (lyophilized). The composition may also be administered intravenously, parenterally, or subcutaneously, as desired. When administered systemically, the therapeutic composition must be sterile, pyrogen-free, and in a parenterally acceptable solution with appropriate consideration to pH, isotonicity, and stability. These conditions are known to those skilled in the art.

[0146] Antibodies for therapeutic use described herein are typically prepared with appropriate carriers, excipients, and other agents incorporated into the formulation to improve transfer, delivery, tolerance, etc. Briefly, the antibody administration formulations described herein are prepared for storage or administration by mixing antibodies of the desired purity with one or more physiologically acceptable carriers, excipients, or stabilizers. These formulations may include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (e.g., Lipofectin®), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, carbowaxes (polyethylene glycol of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowaxes. The formulation may contain buffers such as TRIS HCl, phosphates, citrates, acetates, and other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than approximately 10 residues) peptides such as polyarginine, proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidinone; amino acids such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium, and / or nonionic surfactants such as TWEEN, PLURONICS, or polyethylene glycol.

[0147] Other acceptable carriers, excipients, and stabilizers are well known to those skilled in the art. Any of the aforementioned mixtures may be suitable in the treatments and therapies according to the present invention, provided that the active ingredient in the formulation is not inactivated by formulation, the formulation is physiologically compatible with the route of administration, and is tolerable. For further information, see Baldrick P. “Pharmaceutical excipient development: the need for preclinical guidance.” Regul. Toxicol. Pharmacol. 32(2):210-8 (2000), Wang W. “Lyophilization and development of solid protein pharmaceuticals.” Int. J. Pharm. 203(1-2):1-60 (2000), Charman WN “Lipids, lipophilic drugs, and oral drug delivery—some emerging concepts.” J. Pharm. Sci. 89(8):967-78 (2000), Powell et al. “Compendium of excipients for parenteral formulations” PDA J. Pharm. Sci. Technol. 52:238-311 (1998), and those cited therein.

[0148] Sterile compositions for injection are described in Remington: The Science and Practice of Pharmacy (2020). th As described in Lippincott Williams & Wilkens Publishers (2003), formulations can be made in accordance with conventional pharmaceutical regulations. For example, dissolution or suspension of the active compound in a vehicle, such as water, or natural vegetable oils such as sesame oil, peanut oil, or cottonseed oil, or synthetic fatty vehicle such as ethyl oleate, may be desirable. Buffers, preservatives, antioxidants, etc., can be incorporated in accordance with acceptable pharmaceutical regulations.

[0149] Antibodies can also be administered in sustained-release preparations, which can be released over time. A preferred example of a sustained-release preparation is a semipermeable matrix of a solid hydrophobic polymer containing polypeptides. This matrix may be in the form of a molded article, a film, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol) as described by Langer et al., J. Biomed Mater. Res., (1981) 15:167-277 and Langer, Chem. Tech., (1982) 12:98-105), polylactides (U.S. Patent No. 3,773,919, European Patent No. 58,481), L-glutamic acid and gamma-ethyl-L-glutamic acid copolymers (Sidman et al., Biopolymers, (1983) 22:547-556), non-degradable ethylene-vinyl acetate (Langer et al., cited above), and degradable lactic acid-glycolic acid copolymers, e.g., LUPRON. Examples include Depot (trademark) (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyrate (European Patent No. 133,988).

[0150] Polymers such as ethylene vinyl acetate and lactic acid-glycolic acid can release molecules for more than 100 days, while certain hydrogels release proteins for shorter periods. If encapsulated proteins remain in the body for extended periods, exposure to moisture at 37°C can result in denaturation or aggregation, potentially leading to loss of biological activity and altered immunogenicity. Rational strategies for protein stabilization can be devised depending on the mechanism involved. For example, if the aggregation mechanism is found to be the formation of intermolecular disulfide bonds via disulfide exchange, stabilization can be achieved through modification of sulfhydryl residues, freeze-drying of acidic solutions, control of water content, use of appropriate additives, and development of specific polymer matrix compositions.

[0151] Sustained-release compositions also include preparations of antibody crystals suspended in a suitable formulation that can maintain the crystals in the suspension. These preparations may produce a sustained-release effect when injected subcutaneously or intraperitoneally. Other compositions also include antibodies captured in liposomes. Liposomes containing such antibodies are prepared by methods known to the present day: DE3,218,121; Epstein et al., Proc.Natl.Acad.Sci.USA, (1985)82:3688-3692; Hwang et al., Proc.Natl.Acad.Sci.USA, (1980)77:4030-4034; European Patent No. 52,322; No. 36,676; No. 88,046; No. 143,949; No. 142,641; Japanese Patent Application No. 58-118008; U.S. Patent Nos. 4,485,045 and 4,544,545; and European Patent No. 102,324.

[0152] The dosage of an antibody preparation for a given patient may be determined by the attending physician. When determining the appropriate dosage, the physician may consider various factors known to alter the effect of the therapeutic agent, including, for example, the severity and type of the disease, body weight, sex, diet, time and route of administration, other drug treatments, and other relevant clinical factors. The therapeutically effective dose may be determined either in vitro or in vivo.

[0153] The effective dose of the antibodies described herein for therapeutic use will depend, for example, on the therapeutic objective, the route of administration, and the patient's condition. Therefore, it is preferable for therapists to measure the titer of the dose and change the route of administration as needed to obtain the optimal therapeutic effect. Typical daily doses may range from approximately 0.001 mg / kg to over 100 mg / kg, depending on the factors mentioned above. Typically, clinicians will administer the therapeutic antibody until the dose reaches the desired effect. The course of this treatment can be easily monitored using conventional assays.

[0154] The antibodies described herein are expected to have therapeutic effects in treating symptoms and conditions caused by or related to IL-13 activity.

[0155] Design and manufacture of other therapeutic drugs In accordance with the present invention and based on the activity of antibodies generated and characterized herein with respect to IL-13, advanced antibody therapeutics may be used to treat specific diseases. These advanced therapeutics may include bispecific antibodies, immunotoxins, radiolabeled therapeutics, peptide therapeutics, gene therapeutics, in particular intracellular antibodies, antisense therapeutics, and small molecules.

[0156] In relation to the development of advanced antibody therapeutics in which complement fixation is a desirable characteristic, it may be possible to avoid reliance on complement for cell killing, for example, through the use of bispecific antibodies, immunotoxins, or radiolabeling.

[0157] For example, bispecific antibodies can be produced, including (i) two antibodies conjugated together, one specific for IL-13 and the other specific for a second molecule; (ii) one antibody having one chain specific for IL-13 and a second chain specific for the second molecule; or (iii) a single-chain antibody specific for both IL-13 and the other molecule. Such bispecific antibodies can be produced, for example, using well-known methods related to (i) and (ii) (see, for example, Fanger et al. Immunol Methods 4:72-81 (1994) and Wright and Harris, cited above) and well-known methods related to (iii) (see, for example, Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992)). In any case, the second specificity can be created as desired. For example, the second specificity can be produced for heavy chain activating receptors, including but not limited to CD16 or CD64 (see, e.g., Deo et al. 18:127 (1997)) or CD89 (see, e.g., Valerius et al. Blood 90:4485-4492 (1997)).

[0158] In some embodiments, a product is provided comprising a container containing a composition comprising an anti-IL-13 antibody and an accompanying document or label indicating that the composition may be used to treat diseases mediated by IL-13. Preferably, mammals, more preferably humans, are given the anti-IL-13 antibody. In preferred embodiments, the diseases to be treated include asthma (including both allergic (atopic) and non-allergic (non-atopic)), bronchial asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), hay fever, rhinitis, urticaria, angioedema, allergic dermatitis (including contact dermatitis), Stevens-Johnson syndrome, anaphylactic shock, food allergy, keratitis, conjunctivitis, steroid-resistant glomerulonephritis syndrome, mastocytosis, and fibrotic diseases (e.g., pulmonary fibrosis including idiopathic pulmonary fibrosis, cystic fibrosis). The following are selected from the group consisting of bleomycin-induced fibrosis, hepatic fibrosis, and systemic sclerosis; cancer, e.g., Hodgkin's disease; B-cell proliferative disorders (e.g., B-cell lymphoma, especially mediastinal large B-cell lymphoma); B-cell leukemia; ovarian cancer; diseases characterized by non-malignant B-cell proliferation, e.g., systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, and cryoglobulinemia; diseases characterized by high levels of autoantibodies, e.g., hemolytic anemia, thrombocytopenia, phospholipid syndrome, and pemphigus; inflammatory bowel disease, and graft-versus-host disease.

[0159] In some embodiments, anti-IL-13 antibodies are used to treat asthma. In certain embodiments, the antibody is the 623 antibody or a variant thereof as described herein. In other specific embodiments, the antibody is the 731 antibody or a variant thereof as described herein. [Examples]

[0160] The following examples, including the experiments conducted and the results achieved, are provided for illustrative purposes only and should not be construed as limiting the teachings of this specification.

[0161] Example 1: Antibody preparation Preparation of IL-13 and IL-13 antigen The following IL-13 peptide was used in the experiment described below.

[0162] Recombinant human IL-13 (R&D 213-IL-005; Sequence ID 1): GPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGQFN

[0163] Recombinant human IL-13 (Peprotech 200-13; SEQ ID NO: 2): SPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGRFN

[0164] Recombinant human IL-13 (Peprotech 200-13A; Sequence ID No. 3): MSPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGQFN

[0165] Human IL-13-human Fc fusion protein (including leader sequence; SEQ ID NO: 4): [ka]

[0166] Human IL-13-rabbit Fc fusion protein (including leader sequence; SEQ ID NO: 5): [ka]

[0167] Human IL-13-Mouse IL-13 Helix A (underlined part; Sequence ID No. 6): [ka]

[0168] Human IL-13-Mouse IL-13 Helix B (underlined part; Sequence ID 7): [ka]

[0169] Human IL-13-Mouse IL-13 Helix C (underlined part; Sequence ID No. 68): [ka]

[0170] Human IL-13-Mouse IL-13 Helix D (underlined part; Sequence ID No. 69): [ka]

[0171] As will be understood by those skilled in the art, only a portion of the above residues may actually be involved in epitope formation. For example, in SEQ ID NOs. 66-69 above, the epitope may actually be the helical portion (underlined region) of each peptide.

[0172] Animal immunity Monoclonal antibodies against IL-13 were generated by immunizing XenoMouse® mice (XenoMouse® XMG2L3 and XenoMouse® XMG2, Abgenix, Inc. Fremont, CA). Human IL-13-human Fc fusion protein (SEQ ID NO: 64) or human IL-13-rabbit Fc fusion protein (SEQ ID NO: 65) were used as immunogens for antibody production. Each mouse was immunized via the foot-to-foot route. Animals were immunized on days 0, 4, 7, 11, 14, 18, 21, and 25. For the initial immunization, 10 ug of antigen in CpG / alum was used per mouse. For subsequent booster immunizations, 5 ug of antigen in CpG / alum was used per mouse. For the final booster immunization on day 25, 5 ug of antigen in adjuvant-free PBS was used per mouse. Blood was collected from the animals on day 20, and serum for measuring titer was obtained as described below.

[0173] Potency analysis Titer was determined using a standard protocol. Briefly, a Costar 3368 plate was coated overnight at 4°C with either IL-13 rabbit Fc fusion protein (SEQ ID NO: 65) or full-length rabbit antibody. The plate was washed with Titertek Program ADG9, dried, and blocked with 250 μl of 1% skim milk / 1×PBS. After blocking, the plate was washed again with Titertek Program ADGP and dried. The serum samples were titrated twice, starting with an initial dilution of 1:100 and progressively decreasing to 1:2. The samples were placed in 50 μl / well in 1% skim milk / 1×PBS and incubated at room temperature for 1 hour.

[0174] After washing with Titertek Program ADG9 and drying, the plates were incubated at room temperature for 1 hour with rabbit anti-human Fc secondary antibody conjugated to POD (1:8000 dilution; 50 μL / well) in 1% nonfat skim milk / 1×PBS, exhibiting minimal cross-reactivity to rabbit Fc. The plates were then washed one last time with Titertek Program ADG9 and dried. POD substrate one-step TMB solution (50 μL / well) was added, and the plate was allowed to develop color at room temperature for 30 minutes. The reaction was stopped with 1N HCl (50 μL / well), and the optical density was immediately read with a Titertek Plate Reader.

[0175] As shown in Table 2, three animals with high titers to the IL-13 immunogen were selected for recovery.

[0176] [Table 2]

[0177] Primary screening Highly immunized animals were harvested, and CD19+ B cells were isolated for subsequent B cell culture. The cells were induced to proliferate and terminally differentiate into plasma cells. The supernatant from these plasma cells was screened by ELISA to identify primary wells containing anti-IL-13 specific antibodies. Conventional cultures were performed using 50–500 CD19+ B cells per well to enable the identification of monoclonal antigen-specific B cell cultures.

[0178] In short, IL-13-RbFc was coated overnight at 1 ug / mL onto a Costar 3368 96-well plate. Each plate was washed five times with dH2O, and 40 μL of 1% milk in PBS was added to the plate. Subsequently, 10 μL of B cell supernatant was added to each well. After 1 hour at room temperature, the plate was washed again five times with dH2O. 50 μL of rabbit anti-human Fc-HRP with minimal anti-rabbit cross-reactivity was added to each well (Jackson Laboratories; 1:8000 dilution). After 1 hour at room temperature, the plate was washed again five times with dH2O, and 50 μL of TMB substrate (Neogen) was added to each well. After 30 minutes, the reaction was stopped by adding 50 μL of 1N hydrochloric acid to each well, and the plate was read at a wavelength of 450 nm.

[0179] Representative data obtained from the primary screening are shown in Table 3 below. Wells that showed at least three times the signal of the control well were identified as positive wells. A total of 968 positive antigen-specific B cell wells were identified in the primary screening. All of these wells were then screened in the functional assays described below.

[0180] [Table 3]

[0181] IL-13-induced eotaxin-1 production assay All 968 ELISA-positive wells were screened twice using an IL-13-induced eotaxin-1 release assay. The assay was performed so that only wells containing high concentrations of antibody or high-affinity antibody were identified as neutralizing. A total of 78 neutralizing antibodies were identified as neutralizing in this assay. Specific data from some wells of interest are also shown in Table 4 for illustrative purposes.

[0182] For the assay, HDFa cells were seeded at a rate of 4000 cells / well in 50 μL of medium 106 supplemented with a low serum growth supplement (Cascade) in half the area of ​​a 96-well assay plate. The plate was then incubated overnight at 37°C in 5% CO2. In a separate plate, 12.5 μL of sample antibody, negative control, or positive control was equally divided into sterile 96-well assay plates. Approximately 600 pM of IL-13 was prepared in medium 106 (4 times the final concentration), and approximately 100 ng / mL of TNF-alpha was prepared in medium 106 (2 times the final concentration).

[0183] To initiate the assay, 12.5 μL of IL-13 or medium alone was added to each well and incubated in 5% CO2 at 37°C for 1 hour. After 1 hour of incubation, the HDFa cell medium was carefully removed using a multichannel pipette. 25 μL of TNF-alpha was added to each well. 25 μL of sample / IL-13 was transferred to the HDFa / TNF-alpha wells and the cells were incubated in 5% CO2 at 37°C for 48 hours.

[0184] After 48 hours of incubation, the supernatant from the HFDa assay wells was collected in a 96-well V-bottom plate. The samples were centrifuged at 1500 rpm for 5 minutes.

[0185] 30 μL of sample was assayed for eotaxin-1 release using an assay kit (R&D systems) according to a standard protocol (including the following modifications): (1) 50 μL of capture Ab coated at 2 μg / mL; (2) 50 μL of sample or standard material used (30 μL of sample + 20 μL of medium for a final volume of 50 μL); (3) 50 μL of detection Ab used at 0.1 μg / mL; (4) 50 μL of streptavidin-HRP used at 0.5 μg / mL; and (5) 50 μL of substrate solution.

[0186] [Table 4]

[0187] High antigen (HA) analysis of anti-IL-13 specific B cell culture wells The supernatant for antigen-specific antibody concentration was normalized using the ELISA method. A standard curve was created using a titrated anti-target (IL-13) antibody of known concentration, and the amount of antigen-specific antibody in the supernatant was compared to the standard substance to determine its concentration (see Table 5 below).

[0188] [Table 5]

[0189] The amount of antigen-specific antibody in each well was quantified and plotted against the neutralization data for that well to identify the well with the highest efficacy (Figure 1). The well containing the highest efficacy antibody is the well that best inhibits the antigen with the lowest concentration of antibody (upper left quadrant of the graph).

[0190] Restriction antigen (LA) analysis of anti-IL-13 specific B cell culture wells Restriction antigen analysis is a method for ranking antigen-specific antibodies prepared in B cell culture supernatant by affinity compared to all other antigen-specific antibodies. When the antigen coating is minimal, only the antibody with the highest affinity should be able to bind at any detectable level in equilibrium. (See, for example, International Publication No. 03 / 048730A2, incorporated herein by reference).

[0191] Here, biotinylated IL-13 was conjugated to streptavidin plates at four concentrations (250 ng / mL; 125 ng / mL; 62 ng / mL; and 31 ng / mL) on a 96-well culture plate at room temperature for 1 hour. Each plate was washed five times with dH2O, and 45 μL of 1% milk in PBS containing 0.05% sodium azide was added to the plate. Subsequently, 5 μL of B cell supernatant was added to each well. After shaking in a shaker at room temperature for 18 hours, the plate was washed again five times with dH2O. 50 μL of Gt anti-human (Fc)-HRP was added to each well at 1 μg / mL. After 1 hour at room temperature, the plate was washed again five times with dH2O, and 50 μL of TMB substrate was added to each well. The reaction was stopped by adding 50 μL of 1 M phosphate to each well, and the plate was read at a wavelength of 450 nm.

[0192] However, several wells, including 2388A10 and 2357G11, were clearly superior when measured by OD with the least antigen coating, as shown in Figure 2. The results shown in Figure 2 demonstrate the ability of different antibodies to bind with low concentrations of antigen coating. The antibody giving the highest OD signal has the highest affinity under the conditions of this assay. The remaining clones were further analyzed by combining high-antigen data, measuring specific antibody concentration and restriction antigen production. In this way, it was possible to compare the affinity of antibodies at different concentrations in B cell culture supernatant. The well containing the antibody with the highest affinity is the well with the highest ELISA OD under the condition of the lowest concentration of Ag-specific antibody.

[0193] Based on all screening data, the wells listed in Table 6 were identified for further analysis (plaque assay and microscopy, single-cell PCR, and recombinant expression). Based on potency (total inhibition / specific Ab), five wells were selected: 2372B8, 2383H5, 2398C5, 2401G12, and 2413G11. Based on affinity and inhibition, three wells were selected: 2357G11, 2361G5, and 2384G12. Based solely on neutralization data, two wells were selected: 2388A10 and 2407G11.

[0194] [Table 6]

[0195] IL-13-specific hemolytic plaque assay Cells secreting the target IL-13-specific antibody were isolated using an IL-13-specific hemolytic plaque assay, as commonly described by Babcook et al. (Proc. Natl. Acad. Sci. USA, 93:7843-7848 (1996)), which is incorporated herein by reference. The isolated cells are identified in Table 7 below.

[0196] Biotinylation of sheep red blood cells (SRBCs) SRBCs were stored in RPMI medium as a 25% stock. 1.0 ml of the stock was divided equally into Eppendorf tubes, the cells were spun down (pulsed spin at 8000 rpm (6800 rcf) in a microcentrifuge tube), and the supernatant was removed to obtain a 250 μl SRBC-enriched cell pellet. The cells were then washed twice with 1 ml of PBS (pH 8.6). The cell pellet was then resuspended in 4.75 ml of PBS (pH 8.6) in a 15 ml tube. In a separate 50 ml tube, 2.5 mg of sulfo-NHS biotin was added to 45 ml of PBS (pH 8.6). Once the biotin was completely dissolved, 5 ml of SRBC was added, and the tube was rotated at room temperature for 1 hour. The SRBCs were centrifuged at 3000 g for 5 minutes, the supernatant was removed, and the SRBCs were resuspended in 1 ml of PBS (pH 7.4) in an Eppendorf tube. The SRBCs were washed three times with 1 ml of PBS (pH 7.4). Next, the SRBCs were resuspended in 4.75 ml of immunotherapy medium (RPMI 1640 containing 10% FCS) in a 15 ml tube (5% B-SRBC stock). The stock was stored at 4°C until needed.

[0197] B-SRBC with streptavidin (SA) coating 1 ml of 5% B-SRBC stock was transferred to a new Eppendorf tube. The B-SRBC was pelletized, the supernatant was removed, and the pellet was resuspended in 1.0 ml of PBS (pH 7.4) and repeatedly centrifuged. The washing cycle was repeated twice, and then the B-SRBC pellet was resuspended in 1.0 ml of PBS (pH 7.4) to obtain a final concentration of 5% (vol / vol). 10 μl of 10 mg / ml streptavidin (CalBiochem, San Diego, CA) stock solution was added, the tube was mixed, and rotated at room temperature for 20 minutes. The washing process was repeated, and the SA-SRBC was resuspended in 1 ml of PBS (pH 7.4) (5% (vol / vol)).

[0198] SA-SRBC Human IL-13 Coating SA-SRBCs were coated with a photobiotinylated human IL-13-RbFc fusion at 100 ug / ml, then mixed and rotated at room temperature for 20 minutes. The SRBCs were washed twice with 1.0 ml of PBS (pH 7.4) as described above. The IL-13 coated SRBCs were resuspended in RPMI (+10% FCS) to a final concentration of 5% (volume / volume).

[0199] Quality assessment of IL-13-SRBCs by immunofluorescence (IF) Approximately 10 μl of 5% SA-SRBC and 10 μl of SRBC coated with 5% IL-13 were added to separate, new 1.5 ml Eppendorf tubes containing 40 μl of PBS. A control human anti-IL-13 antibody was added to each SRBC sample at 45 μg / ml. The tubes were rotated at room temperature for 20 minutes, and then the cells were washed three times with 100 μl of PBS. The cells were resuspended in 50 μl of PBS and incubated with 20 μg / mL of Gt anti-human IgG Fc antibody conjugated to Alexa 488 (Molecular Probes, Eugene, OR). The tubes were rotated at room temperature for 20 minutes, then washed with 100 μl of PBS, and the cells were resuspended in 10 μl of PBS. 10 μl of stained cells were spotted onto a clean glass microscope slide, covered with a glass coverslip, observed under fluorescence, and scored on an arbitrary scale from 0 to 4.

[0200] Preparation of plasma cells The contents of single B cell culture wells, already identified by the various assays described above as containing B cell clones secreting the target immunoglobulin, were collected. The well contents were collected by adding 37C RPMI (+10% FCS) using a 100-1000 μL pipettor. The cells were resuspended by pipetting and then transferred to a new 1.5 ml Eppendorf tube (final volume approximately 700-1000 μL). The cells were centrifuged in a microcentrifuge tube at 2500 rpm for 1 minute at room temperature. The tube was then rotated 180 degrees and spun again at 2500 rpm for 1 minute. The frozen medium was removed, and the immune cells were resuspended in 100 μL RPMI (10% FCS) and then centrifuged. This washing with RPMI (+10% FCS) was repeated, and the cells were resuspended in 75 μL of RPMI (+10% FCS) and stored on ice until ready for use.

[0201] Plaque assay To a 75 μL cell sample, 75 μL each of IL-13-coated SRBC (5% (volt / volt) stock, diluted as needed if the SRBC community was too concentrated), 4× guinea pig complement (Sigma, Oakville, ON) stock prepared in RPMI (+10% FCS), and 4× enhancing sera stock (1:900 in RPMI (+10% FCS)) were added. 3-5 μL of the mixture was spotted onto a TC plate lid (BD Biosciences, San Jose, CA), and the spot was covered with undiluted paraffin oil. The slide was incubated at 37°C for a minimum of 1 hour.

[0202] [Table 7]

[0203] Cloning and expression After isolating single plasma cells, mRNA was extracted, and reverse transcriptase PCR was performed to generate cDNA encoding the variable heavy and light chains of antibodies secreted by each cell. The human variable heavy chain region was cloned into an IgG2 expression vector. This vector was constructed by cloning the constant domain of human IgG2 into the multi-cloning site of pcDNA3.1+ / Hygro(Invitrogen, Burlington, ON). The human variable light chain region was cloned into an IgK or IgL expression vector. These vectors were constructed by cloning the constant domain of human IgK or human IgL into the multi-cloning site of pcDNA3.1+ / Neo(Invitrogen, Burlington, ON).

[0204] Next, heavy chain and light chain expression vectors were co-transfected into 60 mm dishes of 70% confluent human embryonic kidney (HEK) 293 cells using lipofectamine. The transfected cells secreted recombinant antibodies with the same specificity as the original plasma cells for 24–72 hours. 3 mL of supernatant was collected from the HEK293 cells, and the secretion of intact antibodies was demonstrated using sandwich ELISA, specifically detecting human IgG. Specificity was confirmed by ELISA through the binding of recombinant antibodies to IL-13.

[0205] The secretion ELISA assay was performed as follows: A control plate was coated overnight with 2 mg / mL goat anti-human IgG H+L, similar to the conjugation plate, and IL-13 was coated onto a Costar Labcoat Universal Binding Polystyrene 96-well plate. The plate was kept overnight at 4°C. The plate was washed five times with dH2O. Recombinant antibody was titrated 1:2 into 7 wells from undiluted lipofection supernatant. The plate was washed five times with dH2O. Goat anti-human IgG Fc-specific HRP conjugate antibody was added at a final concentration of 1 μg / mL at room temperature for 1 hour for the secretion assay and the two conjugation assays. The plate was washed five times with dH2O. TMB was added for 30 minutes to develop color in the plate, and the ELISA was stopped by adding 1M phosphate. Each ELISA plate was analyzed, and the optical density of each well at 450 nm was determined.

[0206] Purification of recombinant anti-IL-13 antibody For larger-scale production, heavy and light chain expression vectors (2.5 μg each per dish) were lipofected into 10 HEK293 cells in 100 mm dishes at 70% confluence. The transfected cells were incubated at 37°C for 4 days, at which point the supernatant (6 mL) was collected and replaced with 6 mL of fresh medium. On day 7, the supernatant was removed and pooled with the initial harvest (120 mL total from the 10 plates).

[0207] Each antibody was purified from the supernatant using Protein-A Sepharose (Amersham Biosciences, Piscataway, NJ) affinity chromatography (1 mL). Antibodies were eluted from the Protein-A column using 500 mL of 0.1 M glycine (pH 2.5). The eluate was dialyzed in PBS (pH 7.4) and filtered to sterilize. The antibodies were analyzed by non-reducing SDS-PAGE to evaluate purity and yield. The concentration was also measured by UV analysis using OD280.

[0208] Example 2: Characterization of recombinant antibodies As described above, the efficacy of recombinant antibodies was analyzed using the eotaxin-1 assay. The results are shown in Table 8 below. This includes the IC50 measured in this assay for mouse IL-13 receptor α2 / FC and human IL-13 receptor α2 / Fc. Figure 3 shows the inhibition rates of IL-13-induced eotaxin release by recombinant antibodies 643 and 731 compared to isotype-matched controls, such as unrelated IgG2 monoclonal antibodies.

[0209] [Table 8]

[0210] Biacore affinity The affinity of six antibodies (602, 623, 643, 693rep1, 693rep2, and 731) for human IL-13 (R&D) was investigated using the BiaCore assay. First, two high-density goat anti-human antibody surfaces were prepared on a CM5 Biacore chip using conventional amine coupling to capture three mAbs at once. All mAbs were diluted to approximately 5 μg / ml using HBS-P electrophoresis buffer containing 100 μg / ml BSA. Using a Biacore2000 instrument, each purified mAb was captured on a different flow cell surface for 1 minute for each IL-13 injection cycle.

[0211] Using the KINJECT command, IL-13(R&D) was injected into all surfaces of mAb 693, 713, and 731 at concentrations of 100.9 nM, 50.4 nM, 25.2 nM, 12.6 nM, 6.30 nM, 3.15 nM, 1.58 nM, and 0.788 nM, and into mAb 602, 623, and 643 at concentrations of 25.2 nM, 12.6 nM, 6.30 nM, 3.15 nM, 1.58 nM, 0.788 nM, and 0.394 nM for 1.5 minutes, followed by dissociation for 20 minutes. The IL-13 samples were prepared in HBS-P electrophoresis buffer containing 100 μg / ml BSA. All samples were injected twice randomly using several mAb capture / buffer KINJECT cycles inserted for dual reference.

[0212] After each cycle, the high-density goat anti-human antibody surface was regenerated with a 12-second pulse of 1 / 100 diluted concentrated phosphoric acid (146 mM, pH 1.5). mAb693 was run twice because there was a surplus flow cell available in the instrument during the final series of medium-resolution experiments.

[0213] Using CLAMP, the data were fitted to a 1:1 interaction model that included the mass transport period. The data for the six antibodies are shown in Table 9.

[0214] [Table 9]

[0215] Dynamic analysis The kinetic measurements of several antibodies were evaluated using the KinExA® method. This method involves solution-based determination of formal affinity measurements at equilibrium.

[0216] 100 μg of each mAb was conjugated to CNBr-activated Sepharose 4B or azulactone beads. The remaining active groups on the beads were blocked as recommended by the manufacturer. The beads were then blocked with 10 mg / ml BSA in 1 M Tris and stored in the blocking solution. For several experiments, the mAbs were directly absorbed and coated onto PMMA beads as recommended by the manufacturer, blocked with 10 mg / ml BSA in PBS, and stored in the blocking solution.

[0217] KinExA experiments were performed using the KinExA3000, an automated flow immunoassay system in which beads conjugated with the relevant mAb act as the solid phase. Briefly, a fixed amount of natural human IL-13 or macaque monkey IL-13 (10–650 pM), prepared by purifying and stimulating PBMCs according to a standard protocol, was incubated with an anti-human IL-13 mAb at a titration concentration starting at 25 nM in sample buffer (PBS containing 0.1% BSA to reduce nonspecific binding). The antigen / antibody complex was incubated at room temperature for 48–168 hours to reach equilibrium. The mixture was collected using the corresponding antibody-conjugated beads to accumulate unbound antigen. The volume and flow rate of the mixture were varied according to the specific signals obtained in each experiment.

[0218] Captured IL-13 was detected using a secondary antibody (either a polyclonal anti-IL-13 antibody or a monoclonal antibody that binds to another epitope) and a solution containing a Cy5 conjugate anti-seed Ig against the secondary antibody in the sample buffer. In some cases, IL-13 bound to beads was detected using a mixture of SA-Cy5 and a biotinylated antibody that binds to an epitope other than the one to which the bead-immobilized antibody binds.

[0219] The signal-to-noise ratio in each experiment was optimized by varying the concentration, volume, and flow rate of the secondary antibody solution. The binding signal was converted to a relative value as the proportion of the control in the absence of hIL-13. Three copies of each sample were measured for all equilibrium experiments. The equilibrium dissociation constant (K) was determined. D The following was obtained from a nonlinear regression analysis of the data using a partially phase-equal coupling model included in the KinExA software. This software uses theoretical K to determine the data points. D By fitting it to the curve, K D Calculate and determine the 95% confidence interval. The 95% confidence interval is low K D and high K D The affinity for natural human IL-13 is summarized in Table 10, and the affinity for natural macaque IL-13 is summarized in Table 11.

[0220]

Table 10

[0221]

Table 11

[0222] For the two antibodies 623 and 731, the association rate constants were investigated using KinExA. The same IL-13 coupled beads were used as the probe, and the "direct" or "flow" method was employed. These methods are identical to the KinExA equilibrium assay with respect to antigen capture, antigen concentration, and antigen detection. In the direct method, antigen and antibody are pre-mixed and then loaded onto the KinExA instrument. In the injection method, the antibody and titrated antigen are mixed together for a fixed period of time prior to reading. Briefly, based on equilibrium experiments, an amount of mAb expected to bind approximately 80% of the antigen was mixed with hIL-13. Free antigen present in the sample was repeatedly probed before equilibrium was reached. Since the binding signal is proportional to the concentration of free antigen in solution, the signal decreased over time until the solution reached an equilibrium state. The volume and flow rate of the antigen-mAb mixture and the Cy5-labeled secondary antibody were varied depending on the mAb tested. Data were analyzed using KinExA analysis software. This software graphically represents the decrease in binding signal over time, and fits the collected data points to the exact solution of the kinetic differential equation for binding. From this curve, K on the optimal solution of was determined (Table 12). K off was K on and K D calculated indirectly from the solutions of.

[0223]

Table 12

[0224] Binding to IL-13 variant proteins We investigated the ability of antibodies 623 and 731 to bind to an IL-13 mutant protein (IL-13Q110R) in which wild-type arginine 110 is replaced with glutamine.

[0225] In short, plates were coated with IL-13RbFc (2.5 μg / mL, 50 μl) by incubation overnight at 4°C in 1× PBS (pH 7.4) and 0.05% azide. Next, the plates were washed with 1× PBS and blocked at room temperature for 30 minutes in 100 μL of 1% nonfat skim milk / 1× PBS.

[0226] IL-13 or IL-13Q110R was pre-incubated with anti-IL-13 antibody at room temperature for 1 hour. IL-13 was titrated stepwise starting from 2000 ng / ml to a final volume of 30 μl / well. 30 μl of mAb was added to each well at 40 ng / ml (sc731, 623) and 80 ng / ml (sc693) to obtain the final concentrations of IL-13 in the first step of the 1000 ng / ml titration, the final concentrations of antibodies 623 and 731 in the first step of the 20 ng / ml titration, and the final concentration of antibody 693 in the first step of the 40 ng / ml titration.

[0227] After pre-incubation, 50 μl / well was transferred from the pre-incubation solution to a plate pre-coated with IL-13RbFc and incubated at room temperature for 30 minutes. The plate was washed, and rabbit anti-Hu IgG Fc HRP was added at a concentration of 200 ng / ml. Incubation was continued for another 30 minutes, followed by washing, and then TMB was added and incubated for another 30 minutes. The reaction was stopped with 1N HCl, and the plate was read as quickly as possible using a Powerwave X340 96-well microplate reader (Biotek).

[0228] As shown in Figure 4, pre-incubation with IL-13 inhibited the binding of both antibodies 623 and 731 to IL-13 coated ELISA plates, while pre-incubation with the IL-13 mutant IL-13Q110R inhibited the binding of 731 to a much higher degree than that of 623.

[0229] Competition of receptor chains The ability of anti-IL-13 antibodies to block the binding of IL-13 to receptors IL-13Rα1 and IL-13Rα2 was investigated. Samples were analyzed using a flow cytometer. The results are shown in Figures 5A and 5B. The data demonstrated the ability of Ab643 (Figure 5A) and Ab731 (Figure 5B) or isotype control antibodies to bind to IL-13 and the receptors involved in the binding process. Specific receptors (e.g., IL-13Ra2, IL-13Ra1, or IL-4R) that bind to IL-13 and allow the antibody to interact with cells were determined using neutralizing antibodies against all possible IL-13 receptors expressed on HDFa cells. A summary of various experimental and predicted results is shown in Figures 5C and 5D (the diagram descriptions will be adjusted where this change is permissible).

[0230] In short, HDFa cells were resuspended in FACS buffer to obtain approximately 200,000 cells / well / 100 μL, and 100 μL of cells were divided equally into 96-well V-bottom plates. Neutralizing antireceptor antibodies (anti-human IL-13Ra1 (R&D Systems), anti-human IL-13Ra2 (R&D Systems), or anti-human IL-4R (R&D Systems)) were diluted twice in FACS buffer to their final concentration (final 10 μg / mL). Anti-IL-13 and control Ab were also diluted twice in FACS buffer to their final concentration (1 μg / mL), similar to IL-13 (human R&D; final 10 ng / mL).

[0231] HDFa cells were centrifuged at 180×g for 7 minutes, and the supernatant was removed by inversion (Plate #1). The cells were resuspended in 50 μL of FACS buffer, and an additional 50 μL of anti-human IL-13Ra1, anti-human IL-13Ra2, anti-human IL-4R, or FACS buffer (without receptor Ab control) was added to the appropriate wells. The cells and antibodies were then incubated on ice for approximately 1.5 hours.

[0232] A second V-bottom plate (plate #2) was used for the pre-incubation of Ab / IL-13. 60 μL of test antibody was divided equally into the V-bottom plate. 60 μL of IL-13 was added to the appropriate wells, and the mixture was incubated on ice for approximately 1.5 hours.

[0233] After incubation, HDFa cells were centrifuged at 180×g for 7 minutes, and the supernatant was removed by inversion. The cells in plate #1 were resuspended in 100 μL of FACS buffer or 100 μL of Ab / IL-13 and incubated for a further 1.5 hours.

[0234] After the second incubation, the cells were centrifuged, washed once with FACS buffer, and 100 μL of FACS buffer, 7AAD, or 2 μg / mL of goat anti-Hu IgG-Fc-Cy5 was added to the appropriate wells.

[0235] The cells and secondary antibody were incubated on ice for 20 minutes, followed by washing with FACS buffer. Next, the cells were resuspended in 100 μL of FACS buffer and divided equally into pre-labeled FACS tubes containing 300 μL of cold FACS buffer.

[0236] Samples were analyzed using a flow cytometer. The results are presented in Figure 5A and Figure 5B. The summary of the aforementioned protocols and predicted results for each antibody is shown in Figure 5C and Figure 5D. As demonstrated by Figure 5A, IL-13 does not bind to HDFa cells in the presence of Ab643. As shown in each panel of Figure 5C, Ab643 appears to prevent IL-13 from binding to its receptor on HDFa cells. As seen in Figure 5B, this is not the case for Ab731. IL-13 causes Ab731 to bind to HDFa cells. As shown in Figure 5D, this binding is not blocked by antibodies against IL-13R alpha 1 or IL-4R, but is blocked by an antibody against IL-13R alpha 2, which indicates that Ab731 prevents IL-13 from binding to IL-13R alpha 1 or IL-4R, but does not prevent it from binding to IL-13R alpha 2.

[0237] The surface expression levels of IL-13Ra1, IL-13Ra2, and IL-4R on HDFa cells were determined by FACS analysis using anti-receptor antibodies. HDFa cells prepared as described above were incubated with anti-receptor antibodies at a concentration of 5 μg / mL on ice for 1 hour. The cells were washed with FACS buffer and incubated with 2 μg / mL of Cy5 secondary (anti-human) antibody on ice for 30 minutes. After washing, the samples were analyzed by flow cytometry. The results are presented in Table 13 below.

[0238] [Table 13]

[0239] Epitope Mapping The epitopes of antibody-IL-13 complexes were analyzed using three methods: 1) SELDI, 2) screening of a random peptide phage display library, and 3) expression of chimeric human / mouse IL-13 molecules. These three methods, combined with structural knowledge of IL-13, provided a consistent view of the relative binding sites and antigenic regions of these mAbs. This enabled the identification of functional epitopes, particularly regions involved in binding to signaling receptors.

[0240] As an initial experiment, dot blot analysis of mAb binding to purified IL-13 protein revealed which antibody bound to which form (linear or conformational) of epitope. mAb693 and 785 bound to the reduced denatured antigen and the linear epitope. mAb602, 623, 643, and 713 bound to non-reduced (conformational epitope) IL-13 but not to the reduced denatured antigen. mAb763 showed no binding. Subsequently, linear epitopes were mapped using a random peptide phage display library. After two rounds of panning of mAb693 against a dodecamer random peptide library expressed on phages, a single specific binding agent was sequenced and aligned to residues 109–120 (helix D) of IL-13 (Figure 6A). IL-13 antibodies were classified into three different bins, but the bins did not always correlate with epitopes determined by other means. One antibody was selected from each bin for SELDI mapping. Table 14 shows the binning results for IL-13 antibodies.

[0241] [Table 14]

[0242] Epitope mapping using SELDI Antibody-antigen complexes were digested with high concentrations of Lys-C and Asp-N. Next, epitopes were identified by SELDI and then by the mass of the resulting fragments. Table 15 shows the predicted masses of peptides digested with the endoproteinase Lys-C.

[0243] [Table 15]

[0244] The masses identified after cleavage were 6842.8 (for peptide fragments 45-108), 7733.7 (for peptide fragments 45-116), and 9461.4 (for peptide fragments 21-108). Therefore, it was determined that the binding site for mAb713 is located within residues 45-108 of IL-13.

[0245] Peptide array for mapping conformational epitopes A peptide array of 101 dodecamer peptides, corresponding to residues 21-132 of the IL-13 sequence, was constructed (SIGMA-Genosys). Each consecutive peptide was shifted by one amino acid from the previous amino acid, resulting in a nested, duplicated library. The array was probed with mAb713, and the PVDF membrane was incubated with an HRP-conjugated secondary antibody, followed by enhanced chemiluminescence to detect the binding of mAb713 to the peptides. Two consecutive spots corresponding to amino acids 70-80 of IL-13 and three consecutive spots corresponding to amino acids 83-92 of IL-13 were observed.

[0246] Epitope mapping using mouse IL-13 chimeric molecules Four new mouse chimeras were created by shuffling the mouse sequences of helix A, B, C, and D with human sequences. The helix positions are shown in Figure 6B. None of the mAbs bound to mouse IL-13. The four chimeras are as follows: [ka] [ka] [ka] [ka]

[0247] Next, the chimeric protein was expressed, and the secreted IL-13 chimeric protein was detected by ELISA assay. The results are summarized in Table 16. "*" indicates weak binding in the sandwich ELISA.

[0248] [Table 16]

[0249] The results of the three above-mentioned studies on the IL-13 epitope are summarized in Table 17.

[0250] [Table 17]

[0251] Therefore, several different possible epitope locations appear to be used by the various antibodies disclosed herein.

[0252] Antibody binning analysis The anti-IL-13 antibodies were classified into three different bins by measuring the ability of two antibodies to bind to the antigen simultaneously (one antibody was used to capture the antigen on the beads, and the other antibody was used for detection). The signal on the beads in the absence of the antigen was subtracted from the signal obtained in the presence of the antigen. The signal of each detection antibody was divided by the signal of the capture antibody to determine the binding increment factor, as shown in Figure 7. Next, the antibodies were binned based on similar binding patterns of the capture antibodies. The data confirmed the existence of three bins of antibody binding for the nine detection antibodies tested (Figure 7).

[0253] In short, mouse anti-human IgG1, 2, 3, and 4 (BD Pharmingen 555784) conjugate beads were added to capture antibodies in individual dark Eppendorf tubes (353 µg / mL). The tubes were rotated overnight in the dark at 4°C. The beads were divided equally into each well of a filter plate (2500 beads / well) and washed.

[0254] IL-13-RbIg (5 μg / ml) and control (culture medium only) were added to a filter plate at a rate of 60 μl / well, then incubated on a shaker at room temperature in the dark for 1 hour, and subsequently washed twice.

[0255] Secondary antibodies diluted in culture medium were added at 60 μl / well (one antibody per well). Antibodies were used at the following concentrations (353B-5g / ml; 11.18.31-5μg / ml; 713-0.56μg / ml; 731-1.28μg / ml; 693-2.7μg / ml; 623-5.7μg / ml; 602-11μg / ml; 643-4.3μg / ml; 785-5.5μg / ml; 763-5.7μg / ml; G2 control-5μg / ml). The plates were then incubated at room temperature for 2 hours and washed.

[0256] Biotinylated Mo anti-HuIg G1, 2, 3, and 4 (BD Pharmingen #555785), diluted at 5 μg / ml in the culture medium, were added to each well (60 μl / well), and the plate was incubated on a shaker at room temperature in the dark for 1 hour. After washing, 60 μl / well of streptavidin-PE (5 ug / mL; Pharm #554061), diluted in the culture medium, was added. The plate was incubated on a shaker at room temperature in the dark for 20 minutes and washed twice.

[0257] Each well was carefully pipettered up and down several times to resuspend the beads in 80 μl of storage / blocking buffer (PBS, 10 mg / ml BSA, 0.05 wt / vol% sodium azide). Each well was analyzed by reading the results on a Luminex with a gate set to 8,400–14,500.

[0258] The Luminex platform is a fluorescent bead-based technology that enables multiple assays to be performed simultaneously. The Luminex reader can identify positive signal events in differently coded microspheres. This allows each bead to be coated separately, then the differently coated microspheres to be mixed together, and then the antibody to be bound to each of the different microspheres in a single-step assay. For antibody isotyping, the microspheres were coated in such a way that each bead could specifically bind to a particular heavy or light chain isotype. The microspheres were then mixed together, and the hybridoma supernatant of each antibody was added. After a 20-minute incubation, the microspheres were washed, and the bound antibodies were detected using a fluorescently labeled secondary antibody. The microspheres were then read using the Luminex reader.

[0259] Example 3: Preclinical in vivo data Humanized IL-13 mouse Humanized IL-13 mice were created at Lexicon (The Woodlands, Texas) in which the gene encoding mouse IL-13 was disrupted by insertion of cDNA encoding human IL-13. The mice were backcrossed with the A / J strain to make them reliably susceptible to allergen-induced airway hyperresponsiveness, as previously described (Ewert et al., (2000) Am.J.Respir.Cell.Mol.Biol.).

[0260] To demonstrate that humanized IL-13 mice produce only human IL-13 and not mouse IL-13, we used OVA-specific CD4 derived from humanized IL-13 mice (6-8 weeks old). + Cytokine production from T cells, using CD4 derived from wild-type mice. + The cells were compared with T cells. Mice were sensitized by intraperitoneal injection of 50 μg OVA / 1 mg Inject Alum (Pierce, Rockford, IL) in 0.9% sterile saline or PBS (3 mice per treatment). Seven days after sensitization, the mice were sacrificed and a single-cell suspension of spleen was prepared. Red blood cells were lysed, and 5 × 10⁶ washed spleen cells were placed in complete medium consisting of 10% heat-inactivated FCS, 2 mM L-glutamine, and HL-1 (BioWhittaker, Walkersville, MD) containing 50 mg / L neomycin sulfate. 6 The cells were resuspended at a concentration of cells / ml. Next, splenocytes were cultured at 37°C for 4 days in the presence of 200 μg / ml OVA, and Ag-reactive CD4 was detected. + T cells were generated. CD4 + T cells (5×10 5 Cells (5 × 10⁶ cells / well) were isolated and then treated with mitomycin C (25 μg / ml) derived from wild-type mice to obtain newly isolated splenocytes (5 × 10⁶ cells / well). 5 The cells were incubated with 200 μg / ml of OVA in a 96-well plate (250 μl / well) for 96 hours in complete medium.

[0261] Cell-free culture supernatants were collected and tested for cytokine production. Human and mouse IL-13 (DuoSet, R&D Systems, Minneapolis, MN) concentrations were measured by ELISA according to the manufacturer's protocol. As expected, CD4 from humanized IL-13 mice after in vitro OVA restimulation was measured. + T cells produced human IL-13 but not mouse IL-13 (Figure 8, Panel A). In contrast, CD4 derived from wild-type mice... + T cells produced mouse IL-13 but not human IL-13 (Figure 8, Panel B).

[0262] Airway hyperresponsiveness Anti-IL-13 antibodies 731 and 623 were tested in an OVA-induced asthma model using the humanized IL-13 mice described above. A 24-day protocol was used to measure airway responsiveness to intravenous administration of acetylcholine. Briefly, mice were immunized by intraperitoneal injection of OVA (10 μg; crude grade IV; Sigma) in PBS (0.2 ml). PBS alone was used as a control. Fourteen days after immunization, mice were anesthetized with a mixture of ketamine and xylazine [45 mg and 8 mg (mg / kg) per kilogram of body weight, respectively] and intratracheally exposed to 50 μl of 1.5% OVA solution or an equal volume of PBS as a control.

[0263] Seven days after the initial antigen exposure, mice were again exposed intratracheally to either OVA or PBS. On the day before each exposure (days 13 and 20), 731 and 623 antibodies were administered intraperitoneally at a dose of 100 μg / mouse. Control mice were administered either PBS or an unrelated IgG2 as an isotype control. Three days after the final intratracheal exposure, mice were anesthetized with pentobarbital sodium (90 mg / kg), intubated, and mechanically respirated with a constant tidal volume of air (0.2 ml) at a rate of 120 breaths / min, and paralyzed with decamethonium bromide (25 mg / kg). After ensuring stable airway pressure, acetylcholine was intravenously injected (50 μg / kg), and dynamic airway pressure was measured for 5 minutes. Airway hyperresponsiveness (AHR) to acetylcholine exposure was measured. Airway hyperresponsiveness to acetylcholine exposure is defined by the time-integrated increase in peak airway pressure [Airway pressure-time index (APTI), H2O (centimeters) × seconds]. *P < 0.05 compared to the OVA + IgG2 control group [One-way ANOVA, followed by Fisher's minimum significance test for multiple comparisons]. Treatment with 731 or 623 resulted in complete recovery of OVA-induced AHR (Figure 9). In this example, complete recovery means that the addition of the antibody with OVA produced an effect similar to that of adding only the antibody (e.g., IgG2) in the absence of OVA.

[0264] OVA-induced mucus production An 18-day protocol was used to measure OVA-induced mucus production. On days 0 and 7, mice were subcutaneously primed with 2 mg of ovalbumin (OVA, 25 μg; crude grade IV) (Sigma) in Imject Alum. After anesthesia with isoflurane, 50 μl of 1.5% OVA solution in PBS was intranasally exposed on days 14, 15, and 17. Control mice were administered either alum as priming or PBS as exposure.

[0265] On days 13, 15, and 17, 731 and 623 antibodies were administered intraperitoneally at a dose of 100 μg / mouse. Control mice were administered PBS. On day 18, mice were sacrificed, and lungs were collected after perfusion. Lung tissue, including the central and peripheral airways, was fixed in 10% formalin, washed and dehydrated in 70% ethanol, embedded in glycol methacrylate, cut into 4 μM sections, placed on slides, and stained with hematoxylin, eosin, and periodate-Schiff (PAS). Lung sections (one section per animal) were examined at 20x magnification. Five regions were randomly selected, and the number of bronchi within each region was counted for each section. Sections were scored on a scale of 0 to 4 (0: <5% PAS). + Goblet cells; 1: 5-25%; 2: 25-50%; 3: 50-75%; 4: >75%). To obtain a histological score for goblet cells (in arbitrary units; expressed as U), the sum of the scores for the airways in each lung was divided by the number of bronchi examined. In the OVA-treated group, 5 out of 8 mice died. No mice died in the other groups. Administration of 731 and 623 effectively restored the OVA-induced increase in mucus-containing cells in the airways (Figure 10). Data are mean ± SE. For the OVA / OVA / PBS group (originally n=8), n=3; for the OVA / OVA / 731 group, n=8; for the OVA / OVA / 623 group, n=4; for the OVA / PBS / PBS group, n=4; and for the alum / OVA / PBS and alum / PBS / PBS groups, n=5. Unpaired Student's t-test showed *p<0.01 for the OVA / OVA / PBS group.

[0266] Example 4: Structural analysis of antibodies The variable heavy and light chains of the antibodies shown in Table 1 were sequenced, and their DNA sequences were determined. Complete sequence information for all anti-IL-13 antibodies, including nucleotide and amino acid sequences, is provided in the sequence listings submitted with this specification.

[0267] Table 18 shows the amino acid sequences of the heavy chain genes of the various IL-13 antibodies described herein. Table 18 also shows the amino acid sequences corresponding to the CDR and framework regions of each antibody, as well as a comparison with their germline sequences.

[0268] Table 19 shows the amino acid sequences of the kappa light chain genes for various IL-13 antibodies described herein. Table 19 also shows the amino acid sequences corresponding to the CDR and framework regions of each antibody, as well as a comparison with their germline sequences.

[0269] Table 20 shows the amino acid sequences of the lambda light chain genes of the various IL-13 antibodies described herein. Table 20 also shows the amino acid sequences corresponding to the CDR and framework regions of each antibody, as well as a comparison with their germline sequences.

[0270] [Table 18]

[0271] [Table 19]

[0272] [Table 20]

[0273] [Table 21]

[0274] [Table 22]

[0275] [Table 23]

[0276] [Table 24]

[0277] Example 5: Production of affinity-matured anti-IL-13 antibody The novel use of mammalian recombinant signal sequence (RSS)-specific recombination for complementarity-determining region (CDR)-targeted protein engineering, based on sequences from antibodies derived from Xenomouse®, closes the species affinity gap for antibody 731 (Ab731).

[0278] Using this non-hypothesis-driven affinity maturation method, the inventors created several antibody variants with improved IL-13 affinity, including an antibody that exhibits high cross-reactivity to cyno IL-13 while having the highest affinity to human IL-13 reported to date.

[0279] HuTARG technology is a novel RSS recombinant-based protein engineering platform linked to cell surface display in mammalian cell culture systems. Briefly, DNA encoding the heavy and light chain complementarity-determining regions (CDRs) of Ab731 was manipulated to include RSS sites using standard molecular biological methods. The resulting plasmid pool encoded individual CDRs that were targets for RSS incorporation, and the success of RSS signal incorporation into each CDR was confirmed by terminal restriction fragment length polymorphism (T-RFLP). The resulting constructs were stably incorporated as a pool into HuTARG cell lines using the Cre-Lox system. HuTARG cells are recombinant competent mammalian cells in which RAG-1-mediated recombinase activity is induced under tetracycline treatment. Upon induction of recombination, each cell undergoes a unique rearrangement involving the removal of the RSS cassette, followed by double-strand break repair in the presence of terminal deoxynucleotidyltransferase (TdT), resulting in incomplete ligation of the recombined segment and sequence variation of the human IgG antibody. This antibody is then expressed on the cell surface by predetermined gene integration into the lox P site, and each cell expresses an antibody with unique and single specificity. Because the heavy chain and light chain sequences were targeted separately, two separate pools of vectors were created and used to generate cell surface display libraries of diversified heavy chain and light chain antibodies. Since recombination occurs directly within the cell and does not require a transformation step, the complexity limit of the library is determined by the number of cells. In this case, the inventors utilized the complexity of 342E6 cells for diversified heavy chains and the complexity of 320E6 cells for diversified light chains. Enhanced affinity variants (determined by higher binding than the parent antibody) were isolated by three rounds of FACS sorting with surface staining of 36 pM recombinant soluble cyno IL-13. The variant antibody sequences selected for enhanced affinity were found to contain insertions and substitutions distributed relatively uniformly across the enriched light chain, consistent with the frequency of RSS incorporation.However, CDR-H3 showed the least change, which is not surprising since CDR-H3 is the primary determinant of epitope recognition by B cells that have left the bone marrow. Insertions and deletions were dominant mutations observed in affinity-rich FACS-selected cells.

[0280] PCR rescue antibody sequences were cloned and transiently expressed on the surface of HEK293T cells, and their binding to soluble human IL-13 and cyno IL-13 was ranked by FACS analysis. The geometric mean of fluorescence for binding to target proteins was compared using three gates based on cell surface IgG expression. Two of the heavy chain mutants that showed improved binding to cyno IL-13, namely heavy chain 1 (HC1) and HC2, were confirmed by KinExA to have higher affinity than their parental antibodies (Figure 1C, Supplementary Table 20(a)). Similar analysis was performed on light chain mutants, and three light chain sequences (LC1, LC2, and LC3) with higher binding than the parental antibody were identified. Subsequently, these light chain mutants were combined in all possible permutations by pairing them with the best heavy chain mutant in a checkerboard fashion. This led to the identification of three antibodies (MMAb3, MMAb5, and MMAb7) that exhibited enhanced affinity for both cyno IL-13 and human IL-13, and showed stronger binding than antibodies with individual mutations in the light or heavy chain. Their biological potency was evaluated by neutralizing eotaxin 1 release from normal human dermal fibroblast (NHDF) cells stimulated with human IL-13 or cyno IL-13. All antibodies proved to be potent inhibitors of both ligands, and their EC50 was limited by the concentration of IL-13 in the assay. In contrast, parental Ab731 showed no activity against cyno IL-13.

[0281] Using KinExA-based affinity determination, the formal affinities of the newly constructed antibody variants to human and cyno IL-13 targets were determined. It was demonstrated that MMAb3 had an affinity of 5.1 pM for cyno IL-13 and an affinity of 34 fM for human IL-13, thus representing 700-fold and 56-fold improvements, respectively. To the best of our knowledge, the affinity of MMAb7 (and MMAb5 at 142 fM) to human IL-13 protein is among the highest ever recorded in the literature. We previously reported on in vivo anti-IL8 antibodies with sub-picomolecular (610 fM) affinities measured by KinExA technology. Other examples of very high-affinity antibodies include the affinity maturation of the mouse anti-IL-1b antibody XMA005 by site-directed mutagenesis, and its subsequent humanization, XOMA 052, which yields sub-picomolecular antibodies (240 fM and 300 fM, respectively) similarly measured by KinExA technology (Owyang, AMet al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. mAbs 3, 49-60 (2011)).The manipulated anti-fluorescein single-chain antibody was also reported to have a Kd of 270 fM with respect to the small molecule hapten fluorescein, similarly measured by the equilibrium binding method (Boder, ET, Midelfort, KS & Wittrup, KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proceedings of the National Academy of Sciences of the United States of America 97, 10701-10705 (2000); Midelfort, K. Set al. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. Journal of molecular biology 343, 685-701 (2004)).

[0282] [Table 25]

[0283] Example 6: Epitope and Cocrystallization Co-crystal structures of a novel antibody with cynomolgus monkey IL-13 and human IL-13. To understand the molecular determinants of the very high affinity interaction between the MMAb3 antibody and cyno IL-13 and human IL-13, the crystal structure of cyno IL-13 in a complex with the MMAb3 fragment antigen-binding (Fab) at a resolution of 2.1 Å (Figure 2A) was constructed, followed by the creation of homologous models of MMAb1 and MMAb2 bound to the same ligand. The crystal structure of cyno IL-13 in a complex with the MMAb3 Fab revealed that the helix C of IL-13 is oriented parallel to the gap in the Fab, indicating its interposition between the heavy and light chains of the Fab. 1784.8 Å 2The total surface area (SASA) of the embedded solvent is the average surface area observed at the antibody-antigen interface (1500-1600A). 2 Larger than ) 25 A total shape complementarity score (Sc) of 0.714 indicates that the degree of complementarity at the IL-13-Fab interface is average (0.64-0.68). 26 This suggests an even higher level and indicates a broad and well-matched interface between the two molecules.

[0284] The crystal structure explained the high affinity of MMAb3 for cyno IL-13 and human IL-13. MMAb3 differs from its parent Ab731 by three consecutive residues in CDR-H2 (Trp54 / Asp55 / Val56 vs. Ser54 / Gly55 / Gly56) and two consecutive residues on CDR-L1 (Ser32 / Phe33 vs. Thr32 / Cys33) (Figure 11). The first set of residues induces the formation of a π-π stacking channel, where the manipulated residue Trp54 derived from CDR-H2 enhances the π-π stacking interaction with Pro103 of CDR-H2, and further along the channel, leads to similar contact between Tyr104 of CDR-H2 and residues Pro72 and His73 of IL-13, primarily involved in van der Waals contact (Figure 13). Furthermore, the presence of Asp55 and Val56 in place of the parent Gly55 and Gly56 may play a role in further stabilizing the CDR-H2 loop skeleton, but this was difficult to evaluate energetically due to conformational variability associated with the presence of the two subsequent Gly residues. The central role of Trp54 at the binding interface is that of 170.1A, which constitutes almost 10% of all SASAs. 2This is also evidenced by the buried surface area. Therefore, structural evidence suggests that Trp54 is not a direct determinant of affinity or specificity, but rather plays a role in stabilization, and we believe that the two properties are more likely to be driven by interactions from CDR-L1 (Figures 12A and B). Since the CDR-L1 paratopes of MMAb3 and Ab731 differ with respect to two residues (Ser32 / Phe33 vs. Thr32 / Cys33), we attempted to identify a change in the binding interaction in this region that confers greater cross-reactivity between cyno IL-13 and human IL-13. In the crystal structure, Asn68 derived from cyno IL13 is located between Tyr31 and the IL13 skeleton carboxyl derived from residues 73-76. This structure suggests that the narrow space created by these contacts fixes Asn68 in a conformation that allows binding, albeit via suboptimal hydrogen bonding with Tyr31 (Figures 12A and B). In human IL-13, the Ser residue is replaced by Asn68 (Figure 13). Given its smaller size and greater distance from surrounding IL-13 backbone residues, Ser68 is less conformally constrained and better positioned to establish stronger hydrogen bonding with the hydroxyl group of Tyr31, resulting in a tighter bond (consistent with experimental data). In either case, although it is extremely difficult to predict deductively, the conformation of Tyr31 may be stabilized by the downstream manipulated residue Phe33, in contrast to the parental antibody with surrounding cavities, where the bulky aromatic ring occupies the cavity and prevents flipping of the rotational isomer. In the context of the parental antibody in complex with human IL-13, the higher affinity of the Ser68:Tyr31 interaction favors the outward conformation of Tyr31, despite the presence of a cavity surrounding Cys33. This is in contrast to cyno IL-13, where the lower affinity of the Asn68:Tyr31 interaction reverses the tyrosine, occupying the cavity surrounding Cys33 and thereby bringing the internal energy to its minimum. However, this significantly reduces the affinity of the parental antibody for cyno IL-13.

[0285] Example 7: High-affinity anti-IL-13 antibody For stability and viscosity, several mutants were created for the Mmab7 light and heavy chains. These high-affinity anti-IL13 amino acid sequences are listed in Tables 21-22 below.

[0286] [Table 26]

[0287] [Table 27]

[0288] [Table 28]

[0289] [Table 29]

[0290] [Table 30]

[0291] [Table 31]

[0292] [Table 32]

[0293] [Table 33]

[0294] [Table 34]

[0295] Table 35

[0296] Table 36

[0297] Table 37

[0298] Table 38

[0299] Table 39

[0300] Table 40

[0301] Table 41

[0302] Table 42

[0303] Table 43

[0304] Table 44

[0305] Example 8: Use of anti-IL-13 antibody as a diagnostic agent for detecting IL-13 in a sample An enzyme-linked immunosorbent assay (ELISA) can be developed to detect IL-13 in a sample. In this assay, a first fully human monoclonal antibody targeting IL-13 is adsorbed onto a multi-well microtiter plate, such as a 96-well or 384-well microtiter plate, for several hours. The immobilized antibody acts as a capture antibody for any IL-13 that may be present in the test sample. The wells are rinsed and treated with a blocking agent such as milk protein or albumin to prevent nonspecific adsorption of the analyte.

[0306] Next, the wells are treated with a test sample suspected to contain IL-13, or a solution containing a standard amount of the antigen.

[0307] After rinsing off the test sample or standard, the wells are treated with a second fully human monoclonal anti-IL-13 antibody labeled by conjugation with biotin. The labeled anti-IL-13 antibody functions as a detection antibody. After rinsing off any excess second antibody, the wells are treated with avidin-conjugated horseradish peroxidase (HRP) and an appropriate chromogenic substrate. The antigen concentration in the test sample is determined by comparison with a standard curve developed from the standard sample.

[0308] Example 9: Treatment of COPD in humans Identify patients with COPD. Administer an effective dose of the anti-IL-13 antibody disclosed above to the patient via intravenous or subcutaneous injection. Administer a booster immunization 3 weeks later, and then every 3 weeks thereafter. The anti-IL-13 antibody induces mucus production, the development of bronchial epithelial hyperplasia, and inhibition of bronchial smooth muscle spasms. This inhibition of mucus production and smooth muscle contraction reduces airway obstruction and improves airflow.

[0309] Example 10: Treatment of chronic bronchitis in humans Identify patients suffering from chronic obstructive pulmonary disease ("COPD") characterized by chronic bronchitis. Administer an effective dose of the anti-IL-13 antibody disclosed herein by intravenous or subcutaneous injection to the patient. The treatment may be repeated weekly, every two weeks, every three weeks, every four weeks, monthly, or every other month. The anti-IL-13 antibody causes partial or complete inhibition of mucus production and bronchial smooth muscle contraction in inflammatory respiratory tissue. This inhibition of mucus production and smooth muscle contraction reduces airway obstruction and improves ventilation.

[0310] Example 11: Treatment of pulmonary emphysema in humans Identify patients with emphysema. Administer an effective dose of IL-13 antibody to the patient intravenously or subcutaneously. The treatment can be repeated weekly, every two weeks, every three weeks, every four weeks, monthly, or every other month. IL-13 antibody causes partial or complete inhibition of neutrophil chemotaxis in inflammatory respiratory tissue. Inhibition of neutrophil chemotaxis reduces the severity of tissue damage to the lungs and airways caused by the patient's immune response. IL-13 has a direct effect (or at least is assumed to) on the induction of proteases that lead to lung tissue destruction in emphysema.

[0311] Example 12: Treatment of asthma in humans Identify patients suffering from asthma. Administer an effective dose of IL-13 antibody to the patients via intravenous or subcutaneous injection.

[0312] The treatment can be repeated weekly, every two weeks, every three weeks, every four weeks, monthly, or every other month. Anti-IL-13 antibodies reduce the severity of tissue damage to the lungs and airways caused by the patient's immune response.

[0313] Example 13: Treatment of atopic dermatitis in humans Identify patients suffering from atopic dermatitis. Administer an effective dose of IL-13 antibody to the patients intravenously or subcutaneously. The treatment can be repeated weekly, every two weeks, every three weeks, every four weeks, monthly, or every other month.

[0314] Example 14: Optimized sequence for high-affinity anti-IL-13 antibody Manipulation of the MmAb5 / MmAb7 hotspot was initiated with an in silico scan using internal software for chemical trends and consensus deviations from germline sequences. The results revealed four potential isomerization sites (Asp Ser and Asp Gly), one consensus deviation, and one potential Trp oxidation site in the CDR. To assess potential mutations and mitigate risks, the internally derived cocrystal structures of MmAb7 and IL-13 were analyzed for hotspot residue exposure and interaction. From these structures, it was observed that the Asp residue directly interacts with a positively charged residue on the antigen at LC:DS 67-68. To preserve this interaction, adjustments were limited to changes in the Ser residue, and Ala substitutions were selected based on internal experience. At LC:DS 110-111, it was observed that Asp interacts with a positively charged residue on the adjacent CDR, giving it structure. To preserve its function in the molecule, Asp was left unchanged, and DS was changed to DA. In HC:DS 72-73, the isomerization site was found to be exposed on the molecular surface and non-interacting. To improve homogeneity, DS was changed to DA. The HC:DG 109-110 site was observed to be embedded within the structure and not undergo isomerization. G110A mutants were tested individually and found to be inactive. In HC:Q108, the residue was changed to germline residue. Hotspot adjustments at various sites were tested individually and in combination using a rational design. Lead mutant selection was based on production yield, Tm, and functional activity using TARC and eotaxin assays.

[0315] Manipulation of the viscosity of MmAb5 and MmAb7 began with in silico surface analysis of the MmAb7 / IL-13 cocrystal structure using BioLuminate Schrodinger software, which identified charge patches and contributing residues. Key contributing residues were analyzed from the most prominent charge patches to assess potential antigen binding and structural effects. The LC:D3 residue was substituted with Val from another germline. The LC:D87 residue was substituted with Asn from another germline. For optimal patch disruption, the L:D26, L:D33, and L:D110 residues were substituted with Lys. Viscosity adjustments at various sites were tested individually and in combination using a rational design. Lead mutant selection was based on production yield, viscosity measured by cone plate method, Tm, and functional activity using TARC assays.

[0316] The TARC assay measures inhibitory TARC produced by IL-13-sensitive progenitor cells in the presence of IL-13. The anti-IL-13 mAb to be measured for TARC inhibition is serially diluted and added to a set volume of IL-13 (3 ng / mL), then incubated at room temperature for 20 minutes. After incubation, the mAb and IL-13 solution are added to 2e5 cells in a 96-well tissue culture plate and incubated at 37°C and 5% CO2 for 48 hours. After incubation, samples are collected, and TARC is measured using an anti-TARC mAb from the MSD detection kit. Plates are read using an MSD 6000. Dose-response data are analyzed, dose-response curves are constructed, and IC50 levels are calculated using Graph Pad Prism software.

[0317] Mutations of anti-IL-13 monoclonal antibodies also include half-life extension mutations at Eu positions M252Y, S254T, and T256E within Fc, commonly known as YTE mutations. These modifications enhance FcRn binding through the action of antibodies recirculated in circulation after endocytosis by effector-functioning cells. These modifications are used with the intention of extending PK and reducing the required dose and / or frequency of administration. See Figure 14.

[0318] Mutations of anti-IL-13 monoclonal antibodies also include complement hexamer disruption mutations at the Eu position S583K within Fc. By inhibiting mAb hexamer formation as part of the complex effector functional mechanism, these modifications have been observed to reduce the viscosity of the antibody at a given formulation and concentration.

[0319] Embedding by reference All references cited herein, including patents, patent applications, articles, textbooks, etc., and references cited within them, are incorporated herein by reference in their entirety unless they are already incorporated elsewhere.

[0320] Equivalents The foregoing specification is considered sufficient for those skilled in the art to carry out the invention. The foregoing description and examples describe in detail certain preferred embodiments of the invention and represent the best mode intended by the inventors. However, regardless of how detailed the foregoing description has been, it will be understood that the invention can be carried out in many ways and that the invention should be interpreted in accordance with the appended claims and all equivalents thereof.

Claims

1. An antigen-binding protein that specifically binds to human IL-13, comprising a light chain immunoglobulin variable region (VL1) and a heavy chain immunoglobulin variable region (VH), VL1 includes (i) CDRL1 containing the amino acid sequence of SEQ ID NO: 11, (ii) CDRL2 containing the amino acid sequence of SEQ ID NO: 12, and (iii) CDRL3 containing the amino acid sequence of SEQ ID NO:

13. VH is an antigen-binding protein comprising (i) the amino acid sequence of SEQ ID NO: 8, CDRH1, (ii) the amino acid sequence of SEQ ID NO: 9, and (iii) the amino acid sequence of CDRH3, which comprises the amino acid sequence of SEQ ID NO: 10.

Citation Information

Patent Citations

  • Fully human monoclonal antibody against il-13

    JP2008520684A

  • Il-13 binding proteins and uses thereof

    US20160272706A1